<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0408222411
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEVOTIC 500 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharma International Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 513]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI ARABIAN DRUG STORE COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Nevotic&reg; is a fluoroquinolone antibiotic medicine used in adults age 18 years or older to treat certain infections caused by certain germs called bacteria. These bacterial infections include:<br />&bull; Nosocomial pneumonia<br />&bull; Community acquired pneumonia<br />&bull; Acute sinus infection<br />&bull; Acute worsening of chronic bronchitis<br />&bull; Skin infections, complicated and uncomplicated<br />&bull; Chronic prostate infection<br />&bull; Urinary tract infections, complicated and uncomplicated<br />&bull; Acute kidney infection (pyelonephritis)<br />&bull; Inhalation anthrax<br />&bull; Plague<br />Studies of levofloxacin for use in the treatment of plague and anthrax were done in animals only, because plague and anthrax could not be studied in people.<br />Nevotic&reg; should not be used in patients with uncomplicated urinary tract infections, acute bacterial exacerbation of chronic bronchitis, or acute bacterial sinusitis if there are other treatment options available.<br />Nevotic&reg; is also used to treat children who weigh at least 30 Kilograms and may have breathed in anthrax germs, have plague, or been exposed to plague germs.<br />It is not known if Nevotic&reg; is safe and effective in children under 6 months of age.<br />The safety and effectiveness in children treated with Nevotic&reg; for more than 14 days is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Do not take Nevotic&reg;:<br />&bull;If you have ever had a severe allergic reaction to an antibiotic known as a fluoroquinolone, or if you are allergic to levofloxacin or any of the ingredients in Nevotic&reg;.</p><p style="text-align:left">Warnings and precautions:<br />Before you take Nevotic&reg;, tell your doctor:<br />&bull;if you have tendon problems; Nevotic&reg; should not be used in patients who have a history of tendon problems.<br />&bull;If you have a problem that causes muscle weakness (myasthenia gravis); Nevotic&reg; should not be used in patients who have a known history of myasthenia gravis.<br />&bull;If you have central nervous system problems such as seizures (epilepsy).<br />&bull;If you have nerve problems; Nevotic&reg; should not be used in patients who have a history of a nerve problem called peripheral neuropathy.<br />&bull;If you have or anyone in your family has an irregular heartbeat, especially a condition called &ldquo;QT prolongation&rdquo;.<br />&bull;If you have low blood potassium (hypokalemia).<br />&bull;If you have bone problems.<br />&bull;If you have joint problems including rheumatoid arthritis (RA).<br />&bull;If you have kidney problems. You may need a lower dose of Nevotic&reg; if your kidneys do not work well.<br />&bull;If you have liver problems.<br />&bull;If you have diabetes or problems with low blood sugar (hypoglycemia).<br />&bull;If you are pregnant or plan to become pregnant. It is not known if Nevotic&reg; will harm your unborn child.<br />&bull;If you are breast-feeding or plan to breast-feed. It is not known if levofloxacin passes into your breast milk. You and your doctor should decide if you will take Nevotic&reg; or breast-feed. You should not do both.<br />&bull;If you have been diagnosed with an enlargement or &ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).<br />&bull;If you have experienced a previous episode of aortic dissection (a tear in the aorta wall).<br />&bull;If you have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&rsquo;s disease, high blood pressure, or known atherosclerosis).<br />If you feel sudden, severe pain in your abdomen, chest or back, go immediately to an emergency room.<br />Other medicines and Nevotic&reg;<br />Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Nevotic&reg; and other medicines can affect each other causing side effects.<br />Especially tell your doctor if you take:<br />&bull;A steroid medicine.<br />&bull;An anti-psychotic medicine<br />&bull;A tricyclic antidepressant<br />&bull;A water pill (diuretic)<br />&bull;Certain medicines may keep Nevotic&reg; from working correctly. Take Nevotic&reg; Tablets either 2 hours before or 2 hours after taking these medicines or supplements:<br />&bull;An antacid, multivitamin, or other medicines or supplements that have magnesium, aluminum, iron, or zinc.<br />&bull;Sucralfate.<br />&bull;Didanosine.<br />&bull;A blood thinner (warfarin).<br />&bull;An oral anti-diabetes medicine or insulin.<br />&bull;An NSAID (Non-Steroidal Anti-Inflammatory Drug). Many common medicines for pain relief are NSAIDs. Taking an NSAID while you take Nevotic&reg; or other fluoroquinolones may increase your risk of central nervous system effects and seizures.<br />&bull;Theophylline.<br />&bull;A medicine to control your heart rate or rhythm (antiarrhythmics).<br />Ask your doctor if you are not sure if any of your medicines are listed above.<br />Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.<br />Nevotic&reg; with food and drink<br />Nevotic&reg; can be taken with or without food.<br />Pregnancy and breast-feeding<br />Pregnancy<br />If you are pregnant or plan to become pregnant. It is not known if Nevotic&reg; will harm your unborn child.<br />Breast-feeding<br />If you are breast-feeding or plan to breast-feed. It is not known if levofloxacin passes into your breast milk. You and your doctor should decide if you will take Nevotic&reg; or breast-feed. You should not do both.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />Nevotic&reg; can make you feel dizzy and lightheaded. Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how Nevotic&reg; affects you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">&bull;Take Nevotic&reg; exactly as your doctor tells you to take it.<br />&bull;Take Nevotic&reg; at about the same time each day.<br />&bull;Drink plenty of fluids while you take Nevotic&reg;.<br />Avoid sunlamps, tanning beds, and try to limit your time in the sun. Nevotic&reg; can make your skin sensitive to the sun (photosensitivity) and the light from sunlamps and tanning beds. You could get severe sunburn, blisters or swelling of your skin. If you get any of these symptoms while you take Nevotic&reg;, call your doctor right away. You should use a sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight.<br />If your infection does not get better while you take Nevotic&reg;, it may mean that the bacteria causing your infection may be resistant to Nevotic&reg;. If your infection does not get better, call your doctor. If your infection does not get better, Nevotic&reg; and other similar antibiotic medicines may not work for you in the future.<br />If you take more Nevotic&reg; tablets than you should<br />If you take too much Nevotic&reg;, call your doctor or get medical help right away.<br />If you forget to take Nevotic&reg; tablets<br />Do not skip any doses of Nevotic&reg;. If you miss a dose of Nevotic&reg;, take it as soon as you remember. Do not take more than 1 dose in 1 day.<br />If you stop taking Nevotic&reg; tablets<br />Do not stop taking Nevotic&reg;, even if you begin to feel better, until you finish your prescribed treatment unless:<br />&bull;You have tendon problems.<br />&bull;You have a nerve problem.<br />&bull;You have a central nervous system problem.<br />&bull;You have a serious allergic reaction.<br />&bull;Your doctor tells you to stop taking Nevotic&reg;<br />Taking all of your Nevotic&reg; doses will help make sure that all of the bacteria are killed. Taking all of your Nevotic&reg; doses will help you lower the chance that the bacteria will become resistant to Nevotic&reg;.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:129.15pt; text-align:left">&nbsp;</p><p style="margin-left:129.15pt; text-align:left">Like all medicines, <strong>Nevotic</strong><strong>&reg; </strong>can cause side effects, although not everybody gets them.</p><p style="text-align:left">Serious side effects:</p><p style="margin-left:129.15pt; text-align:left"><strong>Nevotic</strong><strong>&reg;</strong><strong>, a fluoroquinolone antibiotic, can cause serious side effects.</strong></p><p style="margin-left:129.15pt; text-align:left">Some of these serious side effects can happen at the same time and could result in death.</p><p style="margin-left:129.15pt; text-align:left">If you have any of the following serious side effects while you take <strong>Nevotic</strong><strong>&reg;</strong>, you should stop taking</p><p style="margin-left:129.15pt; text-align:left"><strong>Nevotic</strong><strong>&reg; </strong>immediately and get medical help right away.</p><p style="text-align:left"><!--[if !supportLists]-->1. <!--[endif]-->Tendon rupture or swelling of the tendon (tendinitis).</p><p style="margin-left:129.15pt; margin-right:0.15pt; text-align:left">&middot;Tendon problems can happen in people of all ages who take <strong>Nevotic</strong><strong>&reg;</strong><strong>. </strong>Tendons are tough cords of tissue that connect muscles to bones.</p><p style="margin-left:129.15pt; text-align:left">Some tendon problems include:</p><p style="margin-left:129.15pt; text-align:left">&middot;Pain.</p><p style="margin-left:129.15pt; text-align:left">&middot;Swelling.</p><p style="margin-left:129.15pt; margin-right:3pt; text-align:left">&middot;Tears, and swelling of tendons including the back of the ankle (Achilles), shoulder, hand, or other tendon sites.</p><p style="margin-left:129.15pt; text-align:left">&middot;The risk of getting tendon problems while you take <strong>Nevotic</strong><strong>&reg; </strong>is higher:</p><p style="margin-left:129.15pt; text-align:left">&middot; If you are over 60 years of age.</p><p style="margin-left:129.15pt; text-align:left">&middot; If you are taking steroids (corticosteroids).</p><p style="margin-left:129.15pt; text-align:left">&middot; If you have had a kidney, heart or lung transplant.</p><p style="margin-left:129.15pt; text-align:left">&middot;Tendon problems can happen in people who do not have the above risk factors when they take</p><p style="margin-left:129.15pt; text-align:left"><strong>Nevotic</strong><strong>&reg;</strong>.</p><p style="margin-left:129.15pt; text-align:left">&middot;Other reasons that can increase your risk of tendon problems can include:</p><p style="margin-left:129.15pt; text-align:left">&middot;Physical activity or exercise.</p><p style="margin-left:129.15pt; text-align:left">&middot;Kidney failure.</p><p style="margin-left:129.15pt; text-align:left">&middot;Tendon problems in the past, such as in people with rheumatoid arthritis (RA).</p><p style="margin-left:129.15pt; margin-right:3pt; text-align:left">&middot;Stop taking <strong>Nevotic</strong><strong>&reg; </strong>immediately and get medical help right away at the first sign of tendon pain, swelling or inflammation. Avoid exercise and using the affected area.</p><p style="margin-left:129.15pt; margin-right:4.95pt; text-align:left">&middot;The most common area of pain and swelling is the Achilles tendon at the back of your ankle. This can also happen with other tendons. You may need a different antibiotic that is not a fluoroquinolone to treat your infection.</p><p style="margin-left:129.15pt; margin-right:3.8pt; text-align:left">&middot;Tendon rupture can happen while you are taking or after you have finished taking <strong>Nevotic</strong><strong>&reg;</strong>. Tendon ruptures can happen within hours or days of taking <strong>Nevotic</strong><strong>&reg; </strong>and have happened up to several months after people have finished taking their fluoroquinolone.</p><p style="margin-left:129.15pt; text-align:left">&middot;Stop taking <strong>Nevotic</strong><strong>&reg; </strong>immediately and get medical help right away if you get any of the following&nbsp; signs or symptoms of a tendon rupture :</p><p style="margin-left:8.9pt; text-align:left"><br />&middot;Hear or feel a snap or pop in a tendon area.</p><p style="margin-left:8.9pt; text-align:left">&middot;Bruising right after an injury in a tendon area.</p><p style="margin-left:8.9pt; text-align:left">&middot;Unable to move the affected area or bear weight.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left"><!--[if !supportLists]-->1. <!--[endif]-->Changes in sensation and possible nerve damage (Peripheral Neuropathy).</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">Damage to the nerves in arms, hands, legs, or feet can happen in people who take fluoroquinolones, including <strong>Nevotic</strong><strong>&reg;</strong>. Stop taking <strong>Nevotic</strong><strong>&reg; </strong>immediately and talk to your doctor right away if you get any of the following symptoms of peripheral neuropathy in your arms, hands, legs, or feet:</p><p style="margin-left:8.9pt; text-align:left">&middot;Pain.</p><p style="margin-left:8.9pt; text-align:left">&middot;Burning.</p><p style="margin-left:8.9pt; text-align:left">&middot;Numbness.</p><p style="margin-left:8.9pt; text-align:left">&middot;Weakness.</p><p style="margin-left:8.9pt; text-align:left">&middot;Tingling</p><p style="margin-left:8.9pt; text-align:left">The nerve damage may be permanent.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left"><!--[if !supportLists]-->2. <!--[endif]-->Central Nervous System (CNS) effects.</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">Seizures have been reported in people who take fluoroquinolone antibacterial medicines, including <strong>Nevotic</strong><strong>&reg;</strong>. Tell your doctor if you have a history of seizures before you start taking <strong>Nevotic</strong><strong>&reg;</strong>. CNS side effects may happen as soon as after taking the first dose of <strong>Nevotic</strong><strong>&reg;</strong>. Stop taking <strong>Nevotic</strong><strong>&reg; </strong>immediately and talk to your doctor right away if you get any of these side effects, or other changes in mood or behavior:</p><p style="margin-left:8.9pt; text-align:left">&middot;Seizures.</p><p style="margin-left:8.9pt; text-align:left">&middot;Hear voices, see things, or sense things that are not there (hallucinations).</p><p style="margin-left:8.9pt; text-align:left">&middot;Feel restless.</p><p style="margin-left:8.9pt; text-align:left">&middot;Tremors.</p><p style="margin-left:8.9pt; text-align:left">&middot;Feel anxious or nervous.</p><p style="margin-left:8.9pt; text-align:left">&middot;Confusion.</p><p style="margin-left:8.9pt; text-align:left">&middot;Depression.</p><p style="margin-left:8.9pt; text-align:left">&middot;Trouble sleeping.</p><p style="margin-left:8.9pt; text-align:left">&middot;Nightmares.</p><p style="margin-left:8.9pt; text-align:left">&middot;Feel lightheaded or dizzy.</p><p style="margin-left:8.9pt; text-align:left">&middot;Feel more suspicious (paranoia).</p><p style="margin-left:8.9pt; text-align:left">&middot;Suicidal thoughts or acts.</p><p style="margin-left:8.9pt; text-align:left">&middot;Headaches that will not go away, with or without blurred vision.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left"><!--[if !supportLists]-->3. <!--[endif]-->Worsening of myasthenia gravis (a problem that causes muscle weakness).</p><p style="margin-left:8.9pt; margin-right:128.85pt; text-align:left">Fluoroquinolones like <strong>Nevotic</strong><strong>&reg; </strong>may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Tell your doctor if you have a history of myasthenia gravis before you start taking <strong>Nevotic</strong><strong>&reg;</strong>. Call your doctor right away if you have any worsening muscle weakness or breathing problems.</p><p style="text-align:left">Other serious side effects:</p><p style="margin-left:8.9pt; text-align:left"><strong>Nevotic</strong><strong>&reg; </strong><strong>can cause serious side effects, including:</strong></p><p style="margin-left:8.9pt; text-align:left">&middot; <strong>Serious allergic reactions.</strong></p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">Allergic reactions can happen in people taking fluoroquinolones, including <strong>Nevotic</strong><strong>&reg;</strong>, even after only 1 dose. Stop taking <strong>Nevotic</strong><strong>&reg; </strong>and get emergency medical help right away if you have any of the following symptoms of a severe allergic reaction:</p><p style="margin-left:8.9pt; text-align:left">&middot; Hives.</p><p style="margin-left:8.9pt; text-align:left">&middot;Trouble breathing or swallowing.</p><p style="margin-left:8.9pt; text-align:left">&middot;Swelling of the lips, tongue, face.</p><p style="margin-left:8.9pt; text-align:left">&middot;Throat tightness, hoarseness.</p><p style="margin-left:8.9pt; text-align:left">&middot;Rapid heartbeat.</p><p style="margin-left:8.9pt; text-align:left">&middot; Faint.</p><p style="margin-left:8.9pt; text-align:left">&middot;Skin rash.</p><p style="margin-left:8.9pt; text-align:left">Skin rash may happen in people taking <strong>Nevotic</strong><strong>&reg;</strong>, even after only 1 dose.</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">Stop taking <strong>Nevotic</strong><strong>&reg; </strong>at the first sign of a skin rash and call your doctor. Skin rash may be a sign of a more serious reaction to <strong>Nevotic</strong><strong>&reg;</strong>.</p><p style="text-align:left">&middot; Liver damage (hepatotoxicity):</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">Hepatotoxicity can happen in people who take <strong>Nevotic</strong><strong>&reg;</strong>. Call your doctor right away if you have unexplained symptoms such as:</p><p style="margin-left:8.9pt; text-align:left">&middot;Nausea or vomiting.</p><p style="margin-left:8.9pt; text-align:left">&middot;Stomach pain.</p><p style="margin-left:8.9pt; text-align:left">&middot;Fever.</p><p style="margin-left:8.9pt; text-align:left">&middot;Weakness.</p><p style="margin-left:8.9pt; text-align:left">&middot;Abdominal pain or tenderness.</p><p style="margin-left:8.9pt; text-align:left">&middot; Itching.</p><p style="margin-left:8.9pt; text-align:left">&middot;Unusual tiredness.</p><p style="margin-left:8.9pt; text-align:left">&middot;Loss of appetite.</p><p style="margin-left:8.9pt; text-align:left">&middot;Light colored bowel movements.</p><p style="margin-left:8.9pt; text-align:left">&middot;Dark colored urine.</p><p style="margin-left:8.9pt; text-align:left">&middot;Yellowing of your skin or the whites of your eyes.</p><p style="margin-left:8.9pt; margin-right:132.55pt; text-align:left">Stop taking <strong>Nevotic</strong><strong>&reg; </strong>and tell your doctor right away if you have yellowing of your skin or white part of your eyes, or if you have dark urine. These can be signs of a serious reaction to <strong>Nevotic</strong><strong>&reg; </strong>(a liver problem).</p><p style="text-align:left">&middot; Intestine infection (Pseudomembranous colitis)</p><p style="margin-left:8.9pt; margin-right:132.55pt; text-align:left">Pseudomembranous colitis can happen with many antibiotics, including <strong>Nevotic</strong><strong>&reg;</strong>. Call your doctor right away if you get watery diarrhea, diarrhea that does not go away, or bloody stools. You may have stomach cramps and a fever. Pseudomembranous colitis can happen 2 or more months after you have finished your antibiotic.</p><p style="text-align:left">&middot; Serious heart rhythm changes (QT prolongation and torsades de pointes)</p><p style="margin-left:8.9pt; text-align:left">Tell your doctor right away if you have a change in your heart beat (a fast or irregular heartbeat), or</p><p style="margin-left:8.9pt; margin-right:133.65pt; text-align:left">if you faint. <strong>Nevotic</strong><strong>&reg; </strong>may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this happening are higher in people:</p><p style="margin-left:8.9pt; text-align:left">&middot;Who are elderly.</p><p style="margin-left:8.9pt; text-align:left">&middot;With a family history of prolonged QT interval.</p><p style="margin-left:8.9pt; text-align:left">&middot;With low blood potassium (hypokalemia).</p><p style="margin-left:8.9pt; text-align:left">&middot;Who take certain medicines to control heart rhythm (antiarrhythmics).</p><p style="text-align:left">&middot; Joint Problems</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">Increased chance of problems with joints and tissues around joints in children can happen. Tell your child&rsquo;s doctor if your child has any joint problems during or after treatment with <strong>Nevotic</strong><strong>&reg;</strong>.</p><p style="text-align:left">&middot; Changes in blood sugar</p><p style="margin-left:8.9pt; margin-right:128.75pt; text-align:left">People who take <strong>Nevotic</strong><strong>&reg; </strong>and other fluoroquinolone medicines with oral anti-diabetes medicines or with insulin can get low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia). Follow your doctor&rsquo;s instructions for how often to check your blood sugar. If you have diabetes and you get low blood sugar while taking <strong>Nevotic</strong><strong>&reg;</strong>, stop taking <strong>Nevotic</strong><strong>&reg; </strong>and call your doctor right away. Your antibiotic medicine may need to be changed.</p><p style="text-align:left">&middot; Sensitivity to sunlight (photosensitivity)</p><p style="margin-left:8.9pt; text-align:left">The most common side effects of <strong>Nevotic</strong><strong>&reg; </strong>include:</p><p style="margin-left:8.9pt; text-align:left">&middot;Nausea.</p><p style="margin-left:8.9pt; text-align:left">&middot;Headache.</p><p style="margin-left:8.9pt; text-align:left">&middot;Diarrhea.</p><p style="margin-left:8.9pt; text-align:left">&middot;Insomnia.</p><p style="margin-left:8.9pt; text-align:left">&middot;Constipation.</p><p style="margin-left:8.9pt; text-align:left">&middot;Dizziness.</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">In children 6 months and older who take <strong>Nevotic</strong><strong>&reg; </strong>to treat anthrax disease or plague, vomiting is also common.</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left"><strong>Nevotic</strong><strong>&reg; </strong>may cause false-positive urine screening results for opiates when testing is done with some commercially available kits. A positive result should be confirmed using a more specific test.</p><p style="margin-left:8.9pt; margin-right:124.55pt; text-align:left">These are not all the possible side effects of <strong>Nevotic</strong><strong>&reg;</strong>. Tell your healthcare provider about any side effect that bothers you or that does not go away.</p><p style="text-align:left">If any of the side effects get serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:8.9pt; text-align:left">Keep out of the reach and sight of children.</p><p style="margin-left:8.9pt; margin-right:132.55pt; text-align:left">Do not use <strong>Nevotic</strong><strong>&reg; </strong>tablets after the expiry date (EXP) which is stated on the blister and the carton. The expiry date refers to the last day of that month.</p><p style="margin-left:8.9pt; text-align:left"><strong>Nevotic</strong><strong>&reg; </strong>tablets: Store below 30&deg;C.</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:8.9pt; text-align:left">The active substance is levofloxacin (hemihydrate).</p><p style="margin-left:8.9pt; margin-right:129pt; text-align:left">The other ingredients are Microcrystalline cellulos, sodium stach glycolate, Povidone K30, colloidal anhydrus silica, magnesium stearate, Opadry OY-L white, black iron oxide, yellow iron oxide, polyethylene glycol 6000.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nevotic® 500mg F/C Tablet, Beige to brownish yellow oval deep biconvex film coated tablet engraved with PhI on one face, packed in PVDC/ Alu blisters, intended for oral use.
Pack size: 7 film coated tablets/blister /Pack.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:8.9pt; margin-right:234.6pt; text-align:left">Pharma International Company Amman - Jordan</p><p style="margin-left:8.9pt; text-align:left">Tel: 00962-6-5158890 / 5157893</p><p style="margin-left:8.9pt; text-align:left">Fax: 00962-6-5154753</p><p style="margin-left:8.9pt; text-align:left">Email: marketing@pic-jo.com</p><p style="text-align:left">&nbsp;</p><p style="margin-left:8.9pt; margin-right:129.75pt; text-align:left">This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="margin-right:130.45pt" dir="RTL"><strong>نيفوتيك</strong><strong>&reg;</strong>&nbsp;هو أحد المضادات الحيوية من مجموعة فلوروكوينولون والتي تستعمل للبالغين الذين تبلغ أعمارهم 18 عاما أو أكبر لعالج</p><p style="margin-right:130.45pt" dir="RTL">التهابات معينة ناتجة عن جراثيم معينة تعرف بالبكتيريا. وتتضمن هذه االلتهابات البكتيرية ما يلي:</p><p style="margin-right:130.45pt" dir="RTL">&middot; التهاب الرئتين المكتسب من المستشفى.</p><p style="margin-right:130.45pt" dir="RTL">&middot; التهاب الرئتين المكتسب من المجتمع.</p><p style="margin-right:130.45pt" dir="RTL">&middot; التهاب الجيوب الحاد.</p><p style="margin-right:130.45pt" dir="RTL">&middot; التفاقم الحاد اللتهاب القصبات الهوائية المزمن.</p><p style="margin-right:130.45pt" dir="RTL">&middot; التهابات الجلد المعقدة وغير المعقدة.</p><p style="margin-right:130.45pt" dir="RTL">&middot; التهاب البروستات المزمن.</p><p style="margin-right:130.45pt" dir="RTL">&middot; التهابات الجهاز البولي المعقدة وغير المعقدة.</p><p style="margin-right:130.45pt" dir="RTL">&middot; التهاب حاد في الكلى )التهاب الكلوة والحويضة.(</p><p style="margin-right:130.45pt" dir="RTL">&middot; استنشاق الجمرة الخبيثة.</p><p style="margin-right:130.45pt" dir="RTL">&middot; الطاعون. تم إجراء دراسات حول استعمال ليفوفلوكساسين لعالج الطاعون و استنشاق الجمرة الخبيثة على الحيوانات فقط، بسبب عدم القدررة على دراسة الطاعون و استنشاق الجمرة الخبيثة عند األشخاص. إذا توفرت خيارات عالج أخرى، يجب عدم استعمال<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;للمرضى الذين يعانون من التهابات الجهاز البولي غير المعقدة، التفاقم</p><p style="margin-right:130.5pt" dir="RTL">الحاد اللتهاب القصبات الهوائية البكتيري المزمن، أو التهاب الجيوب البكتيري الحاد.</p><p style="margin-right:130.45pt" dir="RTL">يستعمل<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;أيضا لعالج األطفال الذين تبلغ أوزانهم 30 كيلوغرام والذين من الممكن أنهم استنشقوا جراثيم الجمرة الخبيثة،</p><p style="margin-right:130.45pt" dir="RTL">يعانون من الطاعون، أو تعرضوا للجراثيم التي تسبب الطاعون.</p><p style="margin-right:130.45pt" dir="RTL">من غير المعروف إذا كان استعمال<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;لألطفال الذين تقل أعمارهم عن 6 أشهر آمن وفعال.</p><p style="margin-right:130.45pt" dir="RTL">إن أمان استعمال وفاعلية<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;لألطفال الذين تم عالجهم باستعماله لمدة تزيد عن 14 يوم غير معروف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-right:130.45pt; text-align:right" dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>نيفو</strong><strong>تيك</strong><strong>&reg;</strong><strong>&nbsp;في الحاالت التالية:</strong></p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا عانيت في السابق من تفاعل تحسسي حاد ألي مضاد حيوي من مجموعة الفلوروكوينولون، أو كنت تعاني من تحسس</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">لليفوفلوكساسين، أو ألي مكونات أخرى في<strong> </strong><strong>نيفوتيك</strong>.<strong>&reg;</strong></p><p>االحتياطات والمحاذير</p><p style="margin-right:130.45pt; text-align:right" dir="RTL"><strong>أخبر</strong><strong> </strong><strong>ط</strong><strong>بيبك</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>نيفوتيك</strong><strong>:</strong><strong>&reg;</strong></p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشاكل في األوتار، يجب عدم استعمال<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;للمرضى الذين عانوا في السابق من مشاكل في األوتار.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشكلة تسبب ضعف العضالت )وهن عضلي وبيل(، يجب عدم استعمال<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;للمرضى الذين عانوا في</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">السابق من الوهن العضلي الوبيل.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشاكل في الجهاز العصبي المركزي مثل نوبات الصرع.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشاكل في األعصاب، يجب عدم استعمال<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;للمرضى الذين عانوا في السابق من مشكلة في األعصاب</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">تعرف باالعتالل العصبي الطرفي.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني أنت أو أي شخص من أفراد عائلتك من عدم انتظام نبضات القلب، خصوصا حالة تعرف بإطالة فترة .QT</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من انخفاض مستوى البوتاسيوم في الدم.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشاكل في العظام.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشاكل في المفاصل بما في ذلك التهاب المفاصل الروماتيزمي.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشاكل في الكلى. قد تحتاج لجرعة أقل من<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;إذا كنت تعاني من قصور في وظيفة الكلى.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشاكل في الكبد.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من داء السكري أو مشاكل يرافقها انخفاض مستوى السكر في الدم.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت حامل أو تخططين للحمل. من غير المعروف إذا كان<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;سوف يسبب أذى للجنين.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت مرضعة أو تخططين للرضاعة الطبيعية. من غير المعروف إذا كان ليفوفلوكساسين يفرز في حليب الثدي. يجب أن تقرري</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">أنت وطبيبك إذا كنت ستتناولين<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;أو االستمرار في الرضاعة. يجب عدم القيام بكليهما معا.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا تم تشخيص &nbsp;اصابتك بتضخم أو )انتفاخ( األوعية الدموية الكبيرة )تنفخ الشريان األورطي أو تنفخ األوعية الدموية الكبيرة</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">الطرفية.(</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا عانيت سابقا من نوبات تمزق الشريان األورطي &nbsp;)تمزق في جدار الشريان األورطي.(</p><p style="margin-left:14.55pt; margin-right:130.45pt; text-align:justify; text-indent:-1.4pt" dir="RTL">&middot; إذا كان لديك تاريخ عائلي من تنفخ الشريان األورطي أو تمزق الشريان األورطي أو عوامل خطورة أخرى أو ظروف مهيئة لذلك )مثل اضطربات األنسجة الضامة مثل متالزمة مارفان، أو متالزمة إهلرز- دانلوس )جلد مفرط المرونة(، أو اضطربات األوعية الدموية مثل التهاب الشريان تاكاياوسو )التهاب األورطي غير المحدد(، التهاب الشريان ذو الخاليا العمالقة، مرض بهجت، ارتفاع</p><p style="margin-right:130.4pt; text-align:right" dir="RTL">ضغط الدم، أو تصلب شرايين المعروف.(</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">إذا شعرت بألم مفاجئ و شديد في البطن ، الصدر أو الظهر، اذهب الى الطوارئ مباشرة .</p><p>تناول أدوية أخرى مع نيفوتيك&reg;</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">أخبر طبيبك عن جميع األدوية التي تتناولها، بما في ذلك األدوية التي يتم الحصول عليها بوصفة طبية أو بدون وصفة، الڤيتامينات،</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">والمكمالت العشبية. من الممكن أن يؤثر<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;و األدوية األخرى على بعضها البعض مما يسبب حدوث آثار جانبية.</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">بشكل خاص أخبر طبيبك إذا كنت تتناول أي مما يلي:</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; أحد األدوية الستيرويدية.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; دواء مضاد للذهان.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; أحد مضادات االكتئاب ثالثية الحلقة.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; أقراص الماء )مدرات البول.(</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; أدوية معينة قد تمنع<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;من العمل بشكل صحيح. تناول أقراص<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;إما قبل ساعتين أو بعد ساعتين من تناول هذه</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">األدوية أو المكمالت التالية:</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; مضادات الحموضة، فيتامينات متعددة، أو أدوية أو مكمالت غذائية أخرى تحتوي على المغنيسيوم، األلمنيوم، الحديد أو الزنك.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; سكرالفيت.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; ديدانوسين.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; األدوية التي تمنع تجلط الدم )وارفارين.(</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; األدوية المضادة لداء السكري التي يتم تناولها عن طريق الفم أو اإلنسولين.</p><p style="margin-left:17.2pt; margin-right:130.45pt; text-align:right; text-indent:-5.75pt" dir="RTL">&middot; األدوية غير الستيرويدية المضادة لاللتهاب. إن العديد من األدوية الشائعة لتخفيف األلم تنتمي إلى مجموعة األدوية غير الستيرويدية المضادة لاللتهاب. قد يسبب تناول أحد األدوية غير الستيرويدية المضادة لاللتهاب خالل فترة تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;أو أدوية أخرى من</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">مجموعة الفلوروكوينولون زيادة خطر التعرض لآلثار الجانبية المتعلقة بالجهاز العصبي المركزي ونوبات الصرع.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; ثيوفيلين.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; أدوية لضبط معدل نبضات القلب أو نظمية القلب.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">إسأل طبيبك إذا لم تكن متأكدا إذا كان أي من أدويتك تم ذكره في األعلى.</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">كن على دراية باألدوية التي تتناولها. احتفظ بقائمة أدويتك واعرضها على طبيبك أو الصيدلي عند إعطائك دواء جديد.</p><p>تناول نيفوتيك&reg;&nbsp;مع الطعام والشراب</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">من الممكن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;مع أو بدون تناول الطعام.</p><p>الحمل والرضاعة الطبيعية</p><p style="margin-right:130.45pt; text-align:right" dir="RTL"><strong>الحمل</strong></p><p style="margin-right:130.45pt; text-align:right" dir="RTL">إذا كنت حامال &nbsp;أو تخططين للحمل، من غير المعروف إذا كان<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;سوف يسبب أذى للجنين.</p><p>الرضاعة الطبيعية</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">إذا كنت مرضعة أو تخططين للرضاعة الطبيعية. من غير المعروف إذا كان ليفوفلوكساسين يفرز في حليب الثدي. يجب أن تقرري</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">أنت وطبيبك إذا كنت ستتناولين<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;أو االستمرار في الرضاعة. يجب عدم القيام بكليهما معا.</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">استشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p>القيادة و استخدام اآلالت</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">قد يسبب<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;الشعور بالدوار والدوخة. تجنب القيادة، تشغيل اآلالت، أو القيام بأي نشاطات تتطلب اليقظة العقلية أو التنسيق إلى</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">أن تتأكد من كيفية تأثير<strong> </strong><strong>نيفوتيك</strong><strong>&reg;</strong>&nbsp;عليك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; تناول<strong> </strong><strong>نيف</strong><strong>وتيك</strong><strong>&reg;</strong>&nbsp;تماما كما أخبرك طبيبك.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; تناول<strong> </strong><strong>نيفوتيك</strong><strong>&reg;</strong>&nbsp;في نفس الوقت تقريبا كل يوم.</p><p style="margin-left:12.0pt; margin-right:130.45pt; text-align:right; text-indent:91.6pt" dir="RTL">&middot; قم بشرب كمية كافية من السوائل خالل تناول<strong> نيفوتيك</strong>.<strong>&reg;</strong>&nbsp;&nbsp;&nbsp; &nbsp;تجنب التعرض لألجهزة المستخدمة السمرار الجلد، وحاول تقليل المدة التي تتعرض فيها ألشعة الشمس. قد يجعل<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;الجلد حساس ألشعة الشمس و لألجهزة المستخدمة السمرار الجلد. قد تتعرض لحروق حادة، تنفط أو تورم الجلد. إذا عانيت من أي من هذه</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">األعراض خالل فترة تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;اتصل مع طبيبك فورا. يجب أن استعمال كريم واقي للشمس و ارتداء قبعة ومالبس تغطي الجلد</p><p style="margin-left:13.6pt; margin-right:130.45pt; text-align:right; text-indent:109.55pt" dir="RTL">إذا كان ال بد من التعرض ألشعة الشمس. إذا لم يتحسن االلتهاب الذي تعاني منه خالل فترة تناول<strong> نيفوتيك</strong><strong>&reg;</strong>، هذا قد يعني بأن البكتيريا التي سببت االلتهاب قد تكون مقاومة <strong>لنيفوتيك</strong>.<strong>&reg;</strong>&nbsp;إذا لم يتحسن االلتهاب اتصل مع طبيبك. إذا لم يتحسن االلتهاب، قد يكون<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;وغيره من األدوية المضادة لاللتهاب</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">المشابهة ال يصلح لعالجك في المرات القادمة.</p><p>إذا تناولت نيفوتيك&reg;&nbsp;أقراص أكثر مما يجب</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">إذا تناولت أكثر مما يجب من أقراص<strong> نيفوتيك</strong><strong>&reg;</strong>، اتصل مع طبيبك أو اطلب الرعاية الطبية فورا.</p><p>إذا نسيت تناول جرعة نيفوتيك&reg;&nbsp;أقراص</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">ال تتخطى أي جرعات من<strong> نيفوتيك</strong>.<strong>&reg;</strong>&nbsp;إذا نسيت تناول جرعة<strong> نيفوتيك</strong><strong>&reg;</strong>، تناولها حال تذكرك. ال تتناول أكثر من جرعة واحدة في اليوم.</p><p>إذا توقفت عن تناول نيفوتيك&reg;&nbsp;أقراص</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">ال تتوقف عن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;حتى إذا بدأت تشعر بتحسن، إلى أن تكمل العالج الموصوف لك إال في الحاالت التالية:</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشاكل في األوتار.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشكلة في األعصاب.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من مشكلة في الجهاز العصبي المركزي.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تعاني من تفاعل تحسسي خطير.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا أخبرك طبيبك بالتوقف عن تناول<strong> </strong><strong>نيفوتيك</strong><strong>.&reg;</strong></p><p style="margin-right:130.5pt; text-align:right" dir="RTL">إن تناول جميع جرعات<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;سوف يساعد في التأكد من أنه قد تم القضاء على جميع البكتيريا. إن تناول جميع جرعات<strong> نيفوتيك</strong><strong>&reg;</strong></p><p style="margin-right:130.5pt; text-align:right" dir="RTL">سوف يساعدك في تقليل الفرصة بأن تصبح البكتيريا مقاومة<strong> لنيفوتيك</strong>.<strong>&reg;</strong></p><p style="margin-right:130.5pt; text-align:right" dir="RTL">إذا كان لديك أي أسئلة إضافية عن استعمال هذا المستحضر، إسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-right:130.45pt; text-align:right" dir="RTL">مثل جميع األدوية، قد يسبب<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p>آثار جانبية خطيرة:</p><p style="margin-right:130.45pt; text-align:right" dir="RTL"><strong>قد</strong><strong> </strong><strong>يسبب</strong><strong> </strong><strong>نيفوتيك</strong><strong>&reg;</strong><strong>،</strong><strong> </strong><strong>وهو</strong><strong> </strong><strong>أحد</strong><strong> </strong><strong>المضادات</strong><strong> </strong><strong>الحيوية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>مجموعة</strong><strong> </strong><strong>الفلوروكوينولون،</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>خطيرة.</strong></p><p style="margin-left:20.25pt; margin-right:130.5pt; text-align:right; text-indent:59.9pt" dir="RTL">بعض هذه اآلثار الجانبية الخطيرة قد تحدث في نفس الوقت وقد تسبب الوفاة. إذا عانيت من أي من اآلثار الجانبية الخطيرة التالية خالل فترة تناول<strong> نيفوتيك</strong><strong>&reg;</strong>، يجب التوقف عن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;فورا واطلب</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">الرعاية الطبية فورا.</p><p>.1 تمزق أو تورم األوتار )التهاب األوتار.(</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; قد تحدث مشاكل األوتار عند األشخاص من جميع األعمار والذين يتناولون<strong> نيفوتيك</strong>.<strong>&reg;</strong>&nbsp;واألوتار هي عبارة عن حبل متين من</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">األنسجة والذي يربط العضالت مع العظام.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">تتضمن بعض مشاكل األوتار ما يلي:</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; ألم.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; تورم.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; تمزق، وتورم األوتار بما في ذلك الوتر الذي يقع في المنطقة الخلفية من الكاحل )الوتر األخلس(، الكتف، اليدين، أو األتار في</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">مواقع أخرى.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; يكون خطر حدوث مشاكل في األوتار أكبر خالل فترة تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;في الحاالت التالية:</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كان عمرك يزيد عن 60 عاما.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا كنت تتناول الستيرويدات )ستيرويدات قشرية.(</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; إذا خضعت في السابق لعملية زرع كلى، قلب أو رئة.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; &nbsp;قد تحدث مشاكل األوتار عند األشخاص الذين ال يعانون من عوامل الخطورة المذكورة في األعلى عند تناولهم<strong> نيفوتيك</strong>.<strong>&reg;</strong></p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; أسباب أخرى قد تزيد من خطر التعرض لمشاكل األوتار والتي قد تتضمن:</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; القيام بنشاط جسدي أو تمرينات رياضية.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; قصور وظيفة الكلى.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; التعرض في السابق لمشاكل األوتار، مثل األشخاص الذين يعانون من التهاب المفاصل الروماتيزمي.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; توقف عن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;فورا واطلب الرعاية الطبية فورا عند ظهور أول عالمة أللم، تورم أو التهاب األوتار. تجنب القيام</p><p style="margin-right:130.5pt; text-align:right" dir="RTL">بالتمرينات &nbsp;الرياضية واستعمال المنطقة المصابة.</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">&middot; يعد الوتر األخلس الواقع في المنطقة الخلفية من الكاحل المنطقة األكثر شيوعا المعرضة لأللم والتورم. قد يحدث هذا أيضا مع أوتار</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">أخرى. قد تحتاج لمضاد حيوي مختلف ال ينتمي إلى مجموعة الفلوروكوينولون</p><p style="margin-right:130.45pt; text-align:right" dir="RTL">لعالج االلتهاب لديك.</p><p style="margin-left:20.2pt; margin-right:130.45pt; text-align:right; text-indent:2.4pt" dir="RTL">&middot; قد يحدث تمزق في الوتر خالل فترة تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;أو بعد االنتهاء من العالج. قد يحدث تمزق في الوتر خالل ساعات أو أيام من تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;و في حاالت استمر لغاية عدة أشهر بعد االنتهاء من تناول المضادات الحيوية التي تنتمي إلى مجموعة الفلوروكوينولون.</p><p style="margin-right:305.7pt; text-align:right" dir="RTL">&middot;توقف عن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;فورا واطلب الرعاية الطبية فورا إذا ظهر لديك أي من عالمات وأعراض تمزق الوتر التالية:</p><p style="margin-right:305.7pt; text-align:right" dir="RTL">&middot; سماع صوت أو اإلحساس بطقطقة في منطقة الوتر.</p><p style="margin-right:305.7pt; text-align:right" dir="RTL">&middot; ظهور الكدمات مباشرة بعد اإلصابة في منطقة الوتر.</p><p style="margin-right:305.7pt; text-align:right" dir="RTL">&middot; عدم القدرة على تحريك المنطقة المصابة أو تحمل الوزن.</p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-left:129.9pt; margin-right:.05pt; text-align:justify; text-indent:57.85pt" dir="RTL"><strong>.2 تغيرات في اإلحساس و احتمالية حدوث تلف في األعصاب )اعتالل عصبي طرفي.( </strong>من الممكن حدوث تلف في أعصاب الذراعين، اليدين، الساقين أو القدمين عند األشخاص الذين يتناولون مضادات حيوية من مجموعة فلوروكوينولون، بما في ذلك<strong> </strong><strong>نيفوتيك</strong>.<strong>&reg;</strong>&nbsp;توقف عن تناول<strong> </strong><strong>نيفوتيك</strong><strong>&reg;</strong>&nbsp;فورا وتحدث مع طبيبك فورا إذا حدث لديك أي من األعراض التالية</p><p style="margin-right:.05pt; text-align:right" dir="RTL">الناتجة عن االعتالل العصبي الطرفي في الذراعين، اليدين، الساقين أو القدمين:</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; ألم.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; حرقة.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; تنمل.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بالضعف.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; اإلحساس بوخز خفيف.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">قد يكون تلف األعصاب دائم.</p><p>&nbsp;</p><p>.3 تأثيرات على الجهاز العصبي المركزي.</p><p style="margin-left:132.15pt; margin-right:.05pt; text-align:justify; text-indent:2.65pt" dir="RTL">تم تسجيل حدوث نوبات صرع عند األشخاص الذين يتناولون مضادات حيوية من مجموعة فلوروكوينولون، بما في ذلك<strong> نيفوتيك</strong>.&reg;&nbsp;&nbsp;&nbsp;أخبر طبيبك إذا عانيت في السابق من نوبات صرع قبل بدء تناول<strong> نيفوتيك</strong>.&reg;&nbsp;قد تحدث آثار جانبية متعلقة بالجهاز العصبي المركزي بعد أول جرعة من<strong> نيفوتيك</strong>.&reg;&nbsp;توقف عن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;فورا وتحدث مع طبيبك فورا إذا حدث لديك أي من اآلثار الجانبية التالية، أو</p><p style="margin-right:.05pt; text-align:right" dir="RTL">تغيرات أخرى في المزاج أو السلوك:</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; نوبات صرع.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; سماع أصوات، رؤية أشياء، أو اإلحساس بأشياء غير موجودة في الواقع )هلوسات.(</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بعدم الراحة.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot;رعاش.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بالقلق أو العصبية.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; ارتباك.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; اكتئاب.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; مشاكل في النوم.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; كوابيس.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بالدوخة أو الدوار.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بمزيد من الشك )ذهان خيالئي.(</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; التفكير باالنتحار أو اإلقدام عليه.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; صداع مستمر، مع أو بدون ضبابية الرؤية.</p><p style="margin-left:135.9pt; margin-right:.05pt; text-align:justify; text-indent:70.0pt" dir="RTL"><strong>.4 ازدياد الوهن العضلي الوبيل سوءا )مشكلة تسبب ضعف العضالت.( </strong>قد تسبب المضادات الحيوية من مجموعة الفلوروكوينولون مثل<strong> </strong><strong>نيفوتيك</strong><strong>&reg;</strong>&nbsp;ازدياد أعراض الوهن العضلي الوبيل سوءا، بما في ذلك ضعف العضالت ومشاكل في التنفس. أخبر طبيبك إذا عانيت في السابق من وهن عضلي وبيل قبل بدء تناول<strong> </strong><strong>نيفوتيك</strong>.<strong>&reg;</strong>&nbsp;اتصل مع</p><p style="text-align:right" dir="RTL">طبيبك فورا إذا عانيت من ازدياد ضعف العضالت سوءا أو مشاكل في التنفس.</p><p>آثار جانبية خطيرة أخرى:</p><p style="margin-right:.05pt; text-align:right" dir="RTL"><strong>قد</strong><strong> </strong><strong>يسبب</strong><strong> </strong><strong>نيف</strong><strong>وتيك</strong><strong>&reg;</strong><strong>&nbsp;</strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>خطيرة</strong><strong> </strong><strong>تتضمن:</strong></p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot;<strong> </strong><strong>تفاعل تحسسي خطير</strong></p><p style="margin-left:134.75pt; text-align:right; text-indent:-.35pt" dir="RTL">قد يحدث تفاعالت تحسسية عند األشخاص الذين يتناولون المضادات الحيوية من مجموعة الفلوروكوينولون، بما في ذلك<strong> نيفوتيك</strong><strong>&reg;</strong>، حتى بعد تناول جرعة واحدة فقط. توقف عن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;واطلب المساعدة الطبية الطارئة فورا إذا عانيت من أي من األعراض</p><p style="text-align:right" dir="RTL">التالية المرافقة لحدوث تفاعل تحسسي حاد:</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; شرى.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; مشاكل في التنفس أو البلع.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; تورم الشفاه، اللسان، الوجه.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; ضيق في الحلق، بحة في الصوت.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; نبض قلب سريع.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; إغماء.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot;طفح جلدي.</p><p style="margin-left:138.8pt; margin-right:.05pt; text-align:right; text-indent:34.65pt" dir="RTL">قد يحدث الطفح الجلدي عند األشخاص الذين يتناولون<strong> نيفوتيك</strong><strong>&reg;</strong>، حتى بعد تناول جرعة واحدة فقط. توقف عن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;عند ظهور أول عالمة للطفح الجلدي واتصل مع طبيبك. قد يكون الطفح الجلدي عالمة لحدوث تفاعل</p><p style="margin-right:.05pt; text-align:right" dir="RTL">أكثر خطورة<strong> </strong><strong>لنيف</strong><strong>وتيك</strong><strong>.</strong><strong>&reg;</strong></p><p>&middot; تلف الكبد )سمية الكبد(</p><p style="text-align:right" dir="RTL">قد تحدث سمية الكبد عند األشخاص الذين يتناولون<strong> نيفوتيك</strong>.<strong>&reg;</strong>&nbsp;اتصل مع طبيبك فورا إذا عانيت من أعراض غير مفسرة مثل:</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بالغثيان أو قيء.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; ألم في المعدة.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; حمى.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بالضعف.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; ألم في البطن أو التألم بلمس منطقة البطن.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; حكة.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; شعور غير معتاد بالتعب.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; فقدان الشهية.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; براز ذو لون فاتح.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; بول ذو لون داكن.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; اصفرار الجلد أو المنطقة البيضاء في العيون.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">توقف عن تناول<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;وأخبر طبيبك فورا إذا عانيت من اصفرار الجلد أو المنطقة البيضاء في العيون، أو إذا كان لون البول داكن.</p><p style="text-align:right" dir="RTL">قد تكون هذه عالمات لتفاعل تحسسي خطير<strong> لنيفوتيك</strong><strong>&reg;</strong>&nbsp;)مشكلة في الكبد.(</p><p style="margin-left:131.1pt; margin-right:.05pt; text-align:justify; text-indent:100.3pt" dir="RTL">&middot;<strong> التهاب األمعاء )التهاب القولون الغشائي الكاذب(</strong> قد يحدث التهاب القولون الغشائي الكاذب مع العديد من المضادات الحيوية، بما في ذلك<strong> نيفوتيك</strong>.<strong>&reg;</strong>&nbsp;اتصل مع طبيبك فورا إذا عانيت من إسهال مائي، إسهال مستمر، أو براز مصحوب بظهور الدم. قد تعاني من معص في المعدة و حمى. قد يحدث التهاب القولون الغشائي</p><p style="margin-right:.05pt; text-align:right" dir="RTL">الكاذب بعد شهرين أو أكثر من إنهاء العالج بالمضاد الحيوي.</p><p>&middot; تغيرات خطيرة في نظمية القلب )إطالة فترة QT و تورسيد دي بوينتس(</p><p style="margin-left:136.15pt; text-align:right; text-indent:-.45pt" dir="RTL">أخبر طبيبك فورا إذا عانيت من تغير في نبضات القلب )نبض قلب سريع أو غير منتظم(، أو عانيت من إغماء. قد يسبب<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;حدوث مشكلة نادرة في القلب تعرف بإطالة فترة .QT قد تسبب هذه الحالة اضطراب نبضات القلب وقد تكون خطيرة جدا. وتكون</p><p style="margin-right:.05pt; text-align:right" dir="RTL">فرصة حدوث هذا أكبر عند األشخاص:</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; كبار السن.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الذين لديهم تاريخ عائلي من إطالة فترة .QT</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الذين يعانون من انخفاض مستوى البوتاسيوم في الدم.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الذين يتناولون أدوية معينة للسيطرة على نظمية القلب )مضادات عدم انتظام نبضات القلب.(</p><p>&middot; مشاكل في المفاصل</p><p style="margin-right:.05pt; text-align:right" dir="RTL">قد تزيد فرصة حدوث مشاكل في المفاصل واألنسجة المحيطة بالمفاصل عند األطفال. أخبر طبيب طفلك إذا كان طفلك يعاني من</p><p style="text-align:right" dir="RTL">مشاكل في المفاصل خالل فترة العالج<strong> بنيفوتيك</strong><strong>&reg;</strong>&nbsp;أو بعد إنهاء العالج.</p><p style="margin-left:134.45pt; margin-right:.05pt; text-align:right; text-indent:115.15pt" dir="RTL">&middot;<strong> تغيرات في مستوى السكر في الدم</strong> قد يعاني األشخاص الذين يتناولون<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;وغيره من األدوية التي تنتمي إلى مجموعة الفلوروكوينولون بشكل متزامن مع األدوية المضادة لداء السكري التي يتم تناولها عن طريق الفم أو مع اإلنسولين من انخفاض مستوى السكر في الدم وارتفاع مستوى السكر في الدم. قم باتباع تعليمات الطبيب فيما يتعلق بتكرار القيام بفحص مستوى السكر في الدم. إذا كنت تعاني من داء السكري وعانيت من انخفاض مستوى السكر في الدم خالل فترة تناول<strong> نيفوتيك</strong><strong>&reg;</strong>، توقف عن تناوله واتصل مع طبيبك فورا. قد يكون هناك حاجة</p><p style="margin-right:.05pt; text-align:right" dir="RTL">لتغيير المضاد الحيوي.</p><p>&middot; التحسس &nbsp;ألشعة الشمس )التحسس الضوئي(</p><p style="margin-right:.05pt; text-align:right" dir="RTL">تتضمن اآلثار الجانبية األكثر شيوعا<strong> لنيفوتيك</strong><strong>&reg;</strong>&nbsp;ما يلي:</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بالغثيان.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; صداع.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; إسهال.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; أرق.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; إمساك.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">&middot; الشعور بالدوار. يعد القيء أيضا من اآلثار الشائعة عند األطفال الذين تبلغ أعمارهم 6 أشهر وأكبر ويتناولون<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;لعالج مرض استنشاق الجمرة</p><p style="margin-right:.05pt; text-align:right" dir="RTL">الخبيثة أو الطاعون.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">قد يسبب<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;نتائج إيجابية خاطئة لفحص البول المتعلق بوجود المواد األفيونية عند استعمال طرق الفحص التجارية المتوفرة.</p><p style="text-align:right" dir="RTL">يجب التأكد عند ظهور نتيجة إيجابية باستعمال طريقة فحص متخصصة أكثر.</p><p style="text-align:right" dir="RTL">ال تعد هذه القائمة جميع اآلثار الجانبية التي قد يسببها<strong> نيفوتيك</strong>.<strong>&reg;</strong>&nbsp;أخبر طبيبك عن أي آثار جانبية قد تزعجك أو تستمر بالظهور.</p><p>إذا ازدادت خطورة أي من اآلثار الجانبية أو إذا الحظت أي آثار جانبية غير مذكورة في هذه النشرة، الرجاء أخبر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-right:.05pt; text-align:right" dir="RTL">يحفظ بعيدا عن متناول األطفال و نظرهم.</p><p style="margin-right:.05pt; text-align:right" dir="RTL">ال تستخدم<strong> نيفوتيك</strong><strong>&reg;</strong>&nbsp;بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط ،الملصق و العلبة الخارجية.</p><p style="text-align:right" dir="RTL">تاريخ الانتهاء يشير إلى اليوم األخير من ذلك الشهر.</p><p style="margin-right:.05pt; text-align:right" dir="RTL"><strong>نيفوتيك</strong><strong>&reg;</strong>&nbsp;أقراص: يحفظ &nbsp;بدرجة حرارة دون 30 &deg;م.</p><p style="text-align:right" dir="RTL">يجب أن لا يتم التخلص من الادوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من األدوية</p><p style="margin-right:.05pt; text-align:right" dir="RTL">التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:140.95pt; margin-right:0.05pt; text-indent:94.5pt" dir="RTL">المادة الفعالة هي ليفوفلوكساسين )هيميهيدريت.( المكونات األخرى هي: ميكروكريستالين سليلوز، جاليكوالت نشا الصوديوم، بوفيدونK30 ، سيليكا غروية ال مائية، ستيرات</p><p dir="RTL">المغنيسيوم، أوبادري أبيض، أكسيد الحديد األسود، أكسيد الحديد األصفر، بولي إيثيلين جاليكول .6000</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right" dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p style="margin-right:.05pt; text-align:right" dir="RTL"><strong>نيفوتيك</strong><strong>&reg;</strong><strong>&nbsp;</strong><strong>500</strong><strong> </strong><strong>ملغم</strong><strong> </strong><strong>أقرا</strong><strong>ص</strong><strong> </strong><strong>مغلفة،</strong> هي أقراص مغلفة بيضاوية الشكل ذات لون عاجي إلى أصفر مائل إلى بني، محدبة الوجهين،</p><p style="margin-right:.05pt; text-align:right" dir="RTL">محفور على أحد األوجه PhI ، معبأة في أشرطة بي ڤي دي سي/ألومنيوم، معدة لالستعمال عن طريق الفم.</p><p style="margin-right:.05pt; text-align:right" dir="RTL"><strong>حجم العبوة:</strong> 7 أقراص مغلفة/شريط/عبوة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:275.75pt; margin-right:.05pt; text-align:right; text-indent:-7.6pt" dir="RTL">الدولية للدواء عمان - األردن</p><p style="margin-right:.05pt; text-align:right">00962 - 6 - 5158890 / 5157893 :الهاتف</p><p style="margin-right:.05pt; text-align:right">00962 - 6 - 5154753 :فاكس</p><p style="margin-right:.05pt; text-align:right">البريد اإللكتروني:&nbsp;</p><p style="margin-left:8.9pt">marketing@pic-jo.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تنقيح هذه النشرة في 2018/11


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nevotic® 500 mg Film Coated Tablets. 
Levofloxacin hemihydrate 500 mg Film Coated Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nevotic® 500 mg: Each film-coated tablet contains 250 mg Levofloxacin hemihydrate. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nevotic® 500mg F/C Tablet, Beige to brownish yellow oval deep biconvex film coated tablet engraved with PhI on one face, packed in PVDC/ Alu blisters, intended for oral use.
Pack size: 7 film coated tablets/blister /Pack.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Nevotic&reg; Tablets are indicated for the treatment of adults (&ge;18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section.<br />Nosocomial Pneumonia<br />Nevotic&reg; is indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal &beta;-lactam is recommended.<br />Community-Acquired Pneumonia: 7 to 14 day Treatment Regimen<br />Nevotic&reg; is indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Posology and method of administration].<br />MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC &ge;2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.<br />Community-Acquired Pneumonia: 5-day Treatment Regimen<br />Nevotic&reg; is indicated in adult patients for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Posology and method of administration].<br />Complicated Skin and Skin Structure Infections<br />Nevotic&reg; is indicated in adult patients for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis.<br />Uncomplicated Skin and Skin Structure Infections<br />Nevotic&reg; is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes.<br />Chronic Bacterial Prostatitis<br />Nevotic&reg; is indicated in adult patients for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis.<br />Inhalational Anthrax (Post-Exposure)<br />Nevotic&reg; is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis in adults and pediatric patients, 6 months of age and older [see Posology and method of administration]. The effectiveness of Nevotic&reg; is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit.<br />Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of Levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged Nevotic&reg; therapy should only be used when the benefit outweighs the risk.<br />Plague<br />Nevotic&reg; is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older [see Posology and method of administration].<br />Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.<br />Complicated Urinary Tract Infections: 5-day Treatment Regimen<br />Nevotic&reg; is indicated in adult patients for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.<br />Complicated Urinary Tract Infections: 10-day Treatment Regimen<br />Nevotic&reg; is indicated in adult patients for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa.<br />Acute Pyelonephritis: 5 or 10-day Treatment Regimen<br />Nevotic&reg; is indicated in adult patients for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.<br />Uncomplicated Urinary Tract Infections<br />Nevotic&reg; is indicated in adult patients for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.<br />Because fluoroquinolones, including Nevotic&reg;, have been associated with serious adverse reactions [see Special warnings and precautions] and for some patients uncomplicated urinary tract infection is self-limiting, reserve Nevotic&reg; for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options.<br />Acute Bacterial Exacerbation of Chronic Bronchitis<br />Nevotic&reg; is indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.<br />Because fluoroquinolones, including Nevotic&reg;, have been associated with serious adverse reactions [see Special warnings and precautions] and for some patients ABECB is self-limiting, reserve Nevotic&reg; for treatment of ABECB in patients who have no alternative treatment options.<br />Acute Bacterial Sinusitis: 5-day and 10&ndash;14 day Treatment Regimens<br />Nevotic&reg; is indicated in adult patients for the treatment of acute bacterial sinusitis (ABS) due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.<br />Because fluoroquinolones, including Nevotic&reg;, have been associated with serious adverse reactions [see Special warnings and precautions] and for some patients ABS is self-limiting, reserve Nevotic&reg; for treatment of ABS in patients who have no alternative treatment options.<br />Usage<br />To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nevotic&reg; and other antibacterial drugs, Nevotic&reg; should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.<br />Culture and susceptibility testing<br />Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology]. Therapy with Nevotic&reg; may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.<br />As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Nevotic&reg;. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Dosage of Nevotic<sup>&reg; </sup>Tablets in Adult Patients with Creatinine Clearance &ge;50 mL/minute </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The usual dose of <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>Tablets is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">These recommendations apply to patients with creatinine clearance &ge; 50 mL/minute. For patients with creatinine clearance less than 50 mL/min, adjustments to the dosing regimen are required [see Posology and method of administration].</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Table 1: Dosage of Nevotic<sup>&reg; </sup>Tablets in Adult Patients with Creatinine Clearance greater than or equal to 50 mL/minute) &nbsp;</strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>&nbsp;</strong></p><table style="width:0px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:12.15pt; vertical-align:top; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Type of Infection* </strong></p></td><td style="height:12.15pt; vertical-align:top; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Dosed Every 24 hours </strong></p></td><td style="height:12.15pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Duration (days)<sup>&dagger;</sup> </strong></p></td></tr><tr><td style="height:6.45pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Nosocomial Pneumonia</p></td><td style="height:6.45pt; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg</p></td><td style="height:6.45pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7 to 14</p></td></tr><tr><td style="height:6.4pt; vertical-align:top; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Community Acquired Pneumonia<sup>&Dagger;</sup></p></td><td style="height:6.4pt; vertical-align:top; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg<sup>&Dagger;</sup></p></td><td style="height:6.4pt; vertical-align:top; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7 to 14<sup>&Dagger;</sup></p></td></tr><tr><td style="height:6.4pt; vertical-align:top; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Community Acquired Pneumonia<sup>&sect;</sup></p></td><td style="height:6.4pt; vertical-align:top; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg&sect;</p></td><td style="height:6.4pt; vertical-align:top; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5<sup>&sect; </sup></p></td></tr><tr><td style="height:6.4pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Complicated Skin and Skin Structure Infections (SSSI)</p></td><td style="height:6.4pt; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg</p></td><td style="height:6.4pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7 to 14</p></td></tr><tr><td style="height:6.4pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Uncomplicated SSSI</p></td><td style="height:6.4pt; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg</p></td><td style="height:6.4pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7 to 10</p></td></tr><tr><td style="height:8.15pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Chronic Bacterial Prostatitis</p></td><td style="height:8.15pt; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg</p></td><td style="height:8.15pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">28</p></td></tr><tr><td style="height:18.0pt; vertical-align:top; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Inhalational Anthrax (Post-Exposure), adult and pediatric patients weighing 50 kg <sup>&THORN;,&szlig;</sup> or greater Pediatric patients weighing 30 kg to less than 50 kg <sup>&THORN;,&szlig;</sup></p></td><td style="height:18.0pt; vertical-align:top; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">see Table 2 below</p></td><td style="height:18.0pt; vertical-align:top; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">60<sup>&szlig;</sup></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">60<sup>&szlig;</sup></p></td></tr><tr><td style="height:18.0pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Plague, adult and pediatric patients weighing 50 kg <sup>&agrave;</sup> or greater Pediatric patients weighing 30 kg to less than 50 kg</p></td><td style="height:18.0pt; vertical-align:top; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">see Table 2 below</p></td><td style="height:18.0pt; vertical-align:top; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">10 to 14</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">10 to 14</p></td></tr><tr><td style="height:12.15pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)<sup>&para; </sup></p></td><td style="height:12.15pt; vertical-align:top; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg</p></td><td style="height:12.15pt; vertical-align:top; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5</p></td></tr><tr><td style="height:12.2pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)<sup>#</sup></p></td><td style="height:12.2pt; vertical-align:top; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">250 mg<sup>#</sup></p></td><td style="height:12.2pt; vertical-align:top; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">10<sup>#</sup></p></td></tr><tr><td style="height:6.4pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Uncomplicated Urinary Tract Infection</p></td><td style="height:6.4pt; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">250 mg</p></td><td style="height:6.4pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">3</p></td></tr><tr><td style="border-color:black; height:6.9pt; width:282.2pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)</p></td><td style="height:6.9pt; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg</p></td><td style="height:6.9pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7</p></td></tr><tr><td style="border-color:black; height:6.9pt; width:282.2pt" rowspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Acute Bacterial Sinusitis (ABS)</p></td><td style="height:6.9pt; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg</p></td><td style="height:6.9pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5</p></td></tr><tr><td style="height:6.9pt; width:96.6pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg</p></td><td style="height:6.9pt; width:61.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">10 to 14</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">* Due to the designated pathogens [see Therapeutic indications].</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&dagger; Sequential therapy (intravenous levofloxacin to oral <strong>Nevotic</strong><sup> </sup>tablets) may be instituted at the discretion of the healthcare provider.</p><p style="margin-left:9.35pt; margin-right:4.5pt; text-align:left; text-indent:-9.4pt">&Dagger; Due to methicillin-susceptible <em>Staphylococcus aureus, Streptococcus pneumoniae </em>(including multi-drug-resistant isolates [MDRSP]), <em>Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila</em>, or <em>Mycoplasma pneumoniae </em>[see Therapeutic indications].</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&sect; Due to <em>Streptococcus pneumoniae </em>(excluding multi-drug-resistant isolates [MDRSP]), <em>Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae</em>, <em>or Chlamydophila pneumoniae </em>[see Therapeutic indications].</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&para; This regimen is indicated for cUTI due to <em>Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis </em>and AP due to <em>E. coli</em>, including cases with concurrent bacteremia.</p><p style="margin-left:9.35pt; margin-right:4.5pt; text-align:left; text-indent:-9.4pt"><sup># </sup>This regimen is indicated for cUTI due to <em>Enterococcus faecalis, Enterococcus cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa</em>; and for AP due to <em>E. coli</em>.</p><p style="margin-left:9.35pt; margin-right:4.5pt; text-align:left; text-indent:-9.4pt"><sup>&THORN; </sup>Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized <em>B. anthracis</em>. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&szlig; The safety of levofloxacin<sup> </sup>in adults for durations of therapy beyond 28 days or in pediatric patients for durations beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see Special warnings and precautions]. Prolonged <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>therapy should only be used when the benefit outweighs the risk.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&agrave; Drug administration should begin as soon as possible after suspected or confirmed exposure to <em>Yersinia pestis</em>. Higher doses of <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>typically used for treatment of pneumonia can be used for treatment of plague, if clinically indicated.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Dosage of Nevotic<sup>&reg;</sup> Tablets in Pediatric Patients with Inhalational Anthrax or Plague</strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The dosage of <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>Tablets for inhalational anthrax (post-exposure) and plague in pediatric patients who weigh 30 kg or greater is described below in Table 2. <strong>Nevotic<sup>&reg;</sup></strong> Tablets cannot be administered to patients who weigh less than 30 kg because of the limitations of the available strength. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Table 2: Nevotic<sup>&reg;</sup></strong> <strong>Tablets Dosage in Pediatric Patients Weighing 30 kg or greater with Inhalational Anthrax (Post-Exposure) and Plague<sup>*</sup></strong></p><p style="text-align:left"><!--[if !supportMisalignedColumns]--></p><p style="text-align:left"><!--[endif]--></p><table style="width:0px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:6.3pt; width:146.1pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Type of Infection* </strong></p></td><td style="height:6.3pt; width:70.3pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Dose </strong></p></td><td style="height:6.3pt; width:83.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Frequency </strong></p></td><td style="height:6.3pt; width:130.8pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Duration&dagger; </strong></p></td></tr><tr><td style="height:6.3pt; vertical-align:top; width:252.3pt" colspan="4"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Inhalational Anthrax (post-exposure)<sup>&Dagger;,&sect; </sup></p></td><td style="height:6.3pt" colspan="2"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="height:12.05pt; width:146.1pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Pediatric patients weighing 50 kg or greater</p></td><td style="height:12.05pt; width:70.3pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg</p></td><td style="height:12.05pt; width:83.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">every 24 hours</p></td><td style="height:12.05pt; width:130.8pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">60 days<sup>&sect;</sup></p></td></tr><tr><td style="height:12.0pt; width:146.1pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Pediatric patients weighing 30 kg to less than 50 kg</p></td><td style="height:12.0pt; width:70.3pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">250 mg</p></td><td style="height:12.0pt; width:83.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">every 12 hours</p></td><td style="height:12.0pt; width:130.8pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">60 days<sup>&sect;</sup></p></td></tr><tr><td style="height:6.35pt; vertical-align:top; width:162.5pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Plague<sup>&para;</sup></p></td><td style="height:6.35pt" colspan="4"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="height:12.0pt; width:146.1pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Pediatric patients weighing 50 kg or greater</p></td><td style="height:12.0pt; width:70.3pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg</p></td><td style="height:12.0pt; width:83.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">every 24 hours</p></td><td style="height:12.0pt; width:130.8pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">10 to 14 days</p></td></tr><tr><td style="border-color:black; height:12.6pt; width:146.1pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Pediatric patients weighing 30 kg to less than 50 kg</p></td><td style="height:12.6pt; width:70.3pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">250 mg</p></td><td style="height:12.6pt; width:83.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">every 12 hours</p></td><td style="height:12.6pt; width:130.8pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">10 to 14 days</p></td></tr><tr><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td></tr></tbody></table><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">* Due to <em>Bacillus anthracis </em>[see Therapeutic indications]<em> </em>and <em>Yersinia pestis </em>[see Therapeutic indications].</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&dagger; Sequential therapy (intravenous levofloxacin injection to oral <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>Tablets) may be instituted at the discretion of the healthcare provider.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&Dagger; Begin <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>Tablets as soon as possible after suspected or confirmed exposure to aerosolized <em>B. anthracis</em>.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>&sect; </sup>The safety of levofloxacin<sup> </sup>in pediatric patients for durations of therapy beyond 14 days has not been studied. [See Special warnings and precautions]. Begin <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>Tablets as soon as possible after suspected or confirmed exposure to <em>Yersinia pestis</em>.&nbsp;</p><p style="margin-left:31.5pt; margin-right:4.5pt; text-align:left; text-indent:-31.5pt"><strong>Dosage Adjustment in Adults with Renal Impairment </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Administer <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>with caution in patients with renal impairment. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced in these patients.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">In patients with renal impairment (creatinine clearance less than 50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance. No adjustment is necessary for patients with a creatinine clearance greater than or equal to 50 mL/minute.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Table 3 shows how to adjust dose based on creatinine clearance.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Table 3: Dosage Adjustment in Adult Patients with Renal Impairment (Creatinine Clearance less than 50 mL/minute)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:17.9pt; vertical-align:top; width:107.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Creatinine Clearance greater than or equal to 50 mL/minute </strong></p></td><td style="height:17.9pt; vertical-align:top; width:106.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Creatinine Clearance 20 to 49 mL/minute </strong></p></td><td style="height:17.9pt; vertical-align:top; width:130.35pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Creatinine Clearance 10 to 19 mL/minute </strong></p></td><td style="height:17.9pt; vertical-align:top; width:98.05pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Hemodialysis or Chronic Ambulatory Peritoneal Dialysis (CAPD) </strong></p></td></tr><tr><td style="height:12.15pt; vertical-align:top; width:107.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg every 24 hours</p></td><td style="height:12.15pt; vertical-align:top; width:106.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg every 48 hours</p></td><td style="height:12.15pt; width:130.35pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg initial dose, then 500 mg every 48 hours</p></td><td style="height:12.15pt; width:98.05pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg initial dose, then 500 mg every 48 hours</p></td></tr><tr><td style="height:11.75pt; vertical-align:top; width:107.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg every 24 hours</p></td><td style="height:11.75pt; width:106.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg initial dose, then 250 mg every 24 hours</p></td><td style="height:11.75pt; width:130.35pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg initial dose, then 250 mg every 48 hours</p></td><td style="height:11.75pt; width:98.05pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg initial dose, then 250 mg every 48 hours</p></td></tr><tr><td style="border-color:black; height:23.65pt; vertical-align:top; width:107.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">250 mg every 24 hours</p></td><td style="height:23.65pt; vertical-align:top; width:106.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">No dosage adjustment required</p></td><td style="height:23.65pt; vertical-align:top; width:130.35pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">250 mg every 48 hours. If treating uncomplicated UTI, then no dosage adjustment is required</p></td><td style="height:23.65pt; vertical-align:top; width:98.05pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">No information on dosing adjustment is available</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Drug Interaction with Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>Tablets should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution [see Interaction with other medicinal products].</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Administration Instructions </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>Tablets can be administered without regard to food.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Hydration for Patients Receiving Nevotic<sup>&reg;</sup></strong><sup> </sup><strong>Tablets </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Adequate hydration of patients receiving <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones [see Undesirable effects].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nevotic® is contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects<br />Fluoroquinolones, including Nevotic&reg;, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting Nevotic&reg;. Patients of any age or without pre-existing risk factors have experienced these adverse reactions [see Special warnings and precautions].<br />Discontinue Nevotic&reg; immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including Nevotic&reg;, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.<br />Tendinitis and Tendon Rupture<br />Fluoroquinolones, including Nevotic&reg;, have been associated with an increased risk of tendinitis and tendon rupture in all ages [see Special warnings and precautions and Undesirable effects]. This adverse reaction most frequently involves the Achilles tendon and has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites. Tendinitis or tendon rupture can occur within hours or days of starting Nevotic&reg; or as long as several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally.<br />The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Other factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. Tendinitis and tendon rupture have been reported in patients taking fluoroquinolones who do not have the above risk factors. Discontinue Nevotic&reg; immediately if the patient experiences pain, swelling, inflammation or rupture of a tendon. Patients should be advised to rest at the first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug. Avoid Nevotic&reg; in patients who have a history of tendon disorders or tendon rupture [see Undesirable effects].<br />Peripheral Neuropathy<br />Fluoroquinolones, including Nevotic&reg;, have been associated with an increased risk of peripheral neuropathy. Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving fluoroquinolones, including Nevotic&reg;. Symptoms may occur soon after initiation of Nevotic&reg; and may be irreversible in some patients [see Special warnings and precautions and Undesirable effects].<br />Discontinue Nevotic&reg; immediately if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness or other alterations of sensation including light touch, pain, temperature, position sense, and vibratory sensation. Avoid fluoroquinolones, including Nevotic&reg;, in patients who have previously experienced peripheral neuropathy [see Undesirable effects].<br />Central Nervous System Effects<br />Fluoroquinolones, including Nevotic&reg;, have been associated with an increased risk of central nervous system (CNS) effects, including convulsions, toxic psychoses, increased intracranial pressure (including pseudotumor cerebri). Fluoroquinolones may also cause central nervous system stimulation which may lead to tremors, restlessness, anxiety, lightheadedness, confusion, hallucinations, paranoia, depression, nightmares, and insomnia. Suicidal thoughts, and attempted or completed suicide may also occur, especially in patients with a medical history of depression, or an underlying risk factor for depression. These reactions may occur following the first dose. If these reactions occur in patients receiving Nevotic&reg;, discontinue Nevotic&reg; and institute appropriate measures. As with other fluoroquinolones, Nevotic&reg; should be used with caution in patients with a known or suspected central nervous system (CNS) disorder that may predispose them to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose them to seizures or lower the seizure threshold (e.g., certain drug therapy, renal dysfunction). [See Undesirable effects, Interaction with other medicinal products].<br />Exacerbation of Myasthenia Gravis<br />Fluoroquinolones, including Nevotic&reg;, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Avoid Nevotic&reg; in patients with a known history of myasthenia gravis [see Undesirable effects].<br />Other Serious and Sometimes Fatal Adverse Reactions<br />Other serious and sometimes fatal adverse reactions, some due to hypersensitivity, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with fluoroquinolones, including Nevotic&reg;. These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following:<br /> Fever, rash, or severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens - Johnson syndrome).<br /> Vasculitis; arthralgia; myalgia; serum sickness.<br /> Allergic pneumonitis.<br /> Interstitial nephritis; acute renal insufficiency or failure.<br /> Hepatitis; jaundice; acute hepatic necrosis or failure.<br /> Anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; agranulocytosis; pancytopenia; and/or other hematologic abnormalities.<br />Discontinue Nevotic&reg; immediately at the first appearance of skin rash, jaundice, or any other sign of hypersensitivity and institute supportive measures [see Undesirable effects].<br />Hypersensitivity Reactions<br />Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported in patients receiving therapy with fluoroquinolones, including Nevotic&reg;. These reactions often occur following the first dose. Some reactions have been accompanied by cardiovascular collapse, hypotension/shock, seizure, loss of consciousness, tingling, angioedema (including tongue, laryngeal, throat, or facial edema/swelling), airway obstruction (including bronchospasm, shortness of breath, and acute respiratory distress), dyspnea, urticaria, itching, and other serious skin reactions. Nevotic&reg; should be discontinued immediately at the first appearance of a skin rash or any other sign of hypersensitivity. Serious acute hypersensitivity reactions may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated [see Undesirable effects].<br />Hepatotoxicity<br />Post-marketing reports of severe hepatotoxicity (including acute hepatitis and fatal events) have been received for patients treated with levofloxacin.No evidence of serious drug-associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days. Most cases of severe hepatotoxicity were not associated with hypersensitivity [see Special warnings and precautions]. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Nevotic&reg; should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see Undesirable effects].<br />Clostridium difficile-Associated Diarrhea<br />Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Nevotic&reg;, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.<br />C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.<br />If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated [see Undesirable effects].<br />Prolongation of the QT Interval<br />Some fluoroquinolones, including Nevotic&reg;, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. Rare cases of torsade de pointes have been spontaneously reported during post-marketing surveillance in patients receiving fluoroquinolones, including Nevotic&reg;. Nevotic&reg; should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval [see Undesirable effects].<br />Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Animals<br />Nevotic&reg; is indicated in pediatric patients (6 months of age and older) only for the prevention of inhalational anthrax (post-exposure) and for plague [see Therapeutic indications]. An increased incidence of musculoskeletal disorders (arthralgia, arthritis, tendinopathy, and gait abnormality) compared to controls has been observed in pediatric patients receiving levofloxacin.<br />In immature rats and dogs, the oral and intravenous administration of levofloxacin resulted in increased osteochondrosis. Histopathological examination of the weight-bearing joints of immature dogs dosed with levofloxacin revealed persistent lesions of the cartilage. Other fluoroquinolones also produce similar erosions in the weight-bearing joints and other signs of arthropathy in immature animals of various species.<br />Blood Glucose Disturbances<br />As with other fluoroquinolones, disturbances of blood glucose, including symptomatic hyper-and hypoglycemia, have been reported with levofloxacin, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. If a hypoglycemic reaction occurs in a patient being treated with levofloxacin, Nevotic&reg; should be discontinued and appropriate therapy should be initiated immediately [see Undesirable effects, Interaction with other medicinal products].<br />Photosensitivity/Phototoxicity<br />Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, &ldquo;V&rdquo; area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of fluoroquinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if photosensitivity/phototoxicity occurs [see Undesirable effects].<br />Development of Drug Resistant Bacteria<br />Prescribing Nevotic&reg; in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.<br />Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.<br />Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet&#39;s disease, hypertension, known atherosclerosis).<br />ln case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins<br />While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of Nevotic&reg; Tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin<br />preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. These agents should be taken at least two hours before or two hours after oral Nevotic&reg; administration.<br />Warfarin<br />No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for R-and S-warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the post-marketing experience in patients that levofloxacin enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and levofloxacin use have been associated with episodes of bleeding. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if levofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding [see Undesirable effects].<br />Antidiabetic Agents<br />Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered [see Special warnings and precautions, Undesirable effects].<br />Non-Steroidal Anti-Inflammatory Drugs<br />The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Nevotic&reg;, may increase the risk of CNS stimulation and convulsive seizures [see Special warnings and precautions].<br />Theophylline<br />No significant effect of levofloacin on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of theophylline on levofloxacin absorption and disposition was observed. However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when Nevotic&reg; is co-administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline levels [see Special warnings and precautions].<br />Cyclosporine<br />No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy<br />volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when co-administered with some other fluoroquinolones. Levofloxacin Cmax and ke were slightly lower while Tmax and t&frac12; were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for Nevotic&reg; or cyclosporine when administered concomitantly.<br />Digoxin<br />No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for Nevotic&reg; or digoxin is required when administered concomitantly.<br />Probenecid and Cimetidine<br />No significant effect of probenecid or cimetidine on the Cmax of levofloxacin was observed in a clinical study involving healthy volunteers. The AUC and t&frac12; of levofloxacin were higher while CL/F and CLR were lower during concomitant treatment of levofloxacin with probenecid or cimetidine compared to levofloxacin alone. However, these changes do not warrant dosage adjustment for Nevotic&reg; when probenecid or cimetidine is co-administered.<br />Interactions with Laboratory or Diagnostic Testing<br />Some fluoroquinolones, including Nevotic&reg;, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Pregnancy<br />Pregnancy Category C. Levofloxacin was not teratogenic in rats at doses as high as 810 mg/kg/day which corresponds to 9.4 times the highest recommended oral human dose based upon relative body surface area. The oral dose of 810 mg/kg/day to rats caused decreased fetal body weight and increased fetal mortality. No teratogenicity was observed when rabbits were dosed orally as high as 50 mg/kg/day which corresponds to 1.1 times the highest recommended oral human dose based upon relative body surface area.<br />There are, however, no adequate and well-controlled studies in pregnant women. Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br />Nursing Mothers<br />Based on data on other fluoroquinolones and very limited data on levofloxacin, it can be presumed that levofloxacin will be excreted in human milk. Because of the potential for serious adverse reactions from levofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Patients should know how they react to levofloxacin before they operate an automobile or machinery or engage in other activities requiring mental alertness and coordination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Serious and Otherwise Important Adverse Reactions </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Disabling and Potentially Irreversible Serious Adverse Reactions [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tendinitis and Tendon Rupture [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Peripheral Neuropathy [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Central Nervous System Effects [see Special warnings and precautions].<em> </em></p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Exacerbation of Myasthenia Gravis [see Special warnings and precautions].<em> </em></p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Other Serious and Sometimes Fatal Reactions [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hypersensitivity Reactions [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hepatotoxicity [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Clostridium difficile</em>-Associated Diarrhea [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Prolongation of the QT Interval [see Special warnings and precautions].<em> </em></p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Musculoskeletal Disorders in Pediatric</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Blood Glucose Disturbances [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Photosensitivity/Phototoxicity [see Special warnings and precautions].</p><p style="margin-left:54pt; margin-right:4.5pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Development of Drug Resistant Bacteria [see Special warnings and precautions].</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Crystalluria and cylindruria have been reported with quinolones, including levofloxacin. Therefore, adequate hydration of patients receiving <strong>Nevotic<sup>&reg;</sup></strong><sup> </sup>should be maintained to prevent the formation of a highly concentrated urine [see Posology and method of administration].</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Clinical Trial Experience </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The data described below reflect exposure to levofloxacin<sup> </sup>in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was &lt; 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with levofloxacin<sup> </sup>for a wide variety of infectious diseases [see Therapeutic indications]. Patients received levofloxacin<sup> </sup>doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. Treatment duration was usually 3-14 days, and the mean number of days on therapy was 10 days.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The overall incidence, type and distribution of adverse reactions was similar in patients receiving levofloxacin<sup> </sup>doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of levofloxacin<sup> </sup>due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily nausea (0.6%); vomiting (0.4%); dizziness (0.3%); and headache (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily nausea (0.6%), vomiting (0.5%); dizziness (0.3%); and headache (0.3%).</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Adverse reactions occurring in &ge;1% of levofloxacin -treated patients and less common adverse reactions, occurring in 0.1 to &lt;1% of levofloxacin -treated patients, are shown in&nbsp; Table 4 and Table 5, respectively. The most common adverse drug reactions (&ge;3%) are nausea, headache, diarrhea, insomnia, constipation, and dizziness.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Table 4: Common (&ge;1%) Adverse Reactions Reported in Clinical Trials with levofloxacin<sup> #</sup></strong></p><table style="width:0px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:12.65pt; vertical-align:top; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>System/Organ Class </strong></p></td><td style="height:12.65pt; vertical-align:top; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Adverse Reaction </strong></p></td><td style="height:12.65pt; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>% (N=7537) </strong></p></td></tr><tr><td style="height:5.9pt; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Infections and Infestations </strong></p></td><td style="height:5.9pt; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">moniliasis</p></td><td style="height:5.9pt; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1</p></td></tr><tr><td style="height:6.0pt; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Psychiatric Disorders </strong></p></td><td style="height:6.0pt; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">insomnia* [see Special warnings and precautions]</p></td><td style="height:6.0pt; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">4</p></td></tr><tr><td style="height:33.25pt; vertical-align:top; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Nervous System Disorders </strong></p></td><td style="height:33.25pt; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">headache</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">dizziness [see Special warnings and precautions]</p></td><td style="height:33.25pt; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">6</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">3</p></td></tr><tr><td style="height:11.65pt; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Respiratory, Thoracic and Mediastinal Disorders </strong></p></td><td style="height:11.65pt; vertical-align:top; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">dyspnea [see Special warnings and precautions]</p></td><td style="height:11.65pt; vertical-align:top; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1</p></td></tr><tr><td style="height:34.75pt; vertical-align:top; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Gastrointestinal Disorders </strong></p></td><td style="height:34.75pt; vertical-align:bottom; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">nausea</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">diarrhea</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">constipation</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">abdominal pain</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">vomiting</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">dyspepsia</p></td><td style="height:34.75pt; vertical-align:bottom; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">3</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">2</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">2</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">2</p></td></tr><tr><td style="height:11.65pt; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Skin and Subcutaneous Tissue Disorders </strong></p></td><td style="height:11.65pt; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">rash [see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">pruritus</p></td><td style="height:11.65pt; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">2</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1</p></td></tr><tr><td style="height:11.75pt; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Reproductive System and Breast Disorders </strong></p></td><td style="height:11.75pt; vertical-align:top; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">vaginitis</p></td><td style="height:11.75pt; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1&dagger;</p></td></tr><tr><td style="border-color:black; height:17.9pt; vertical-align:top; width:165.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>General Disorders and Administration Site Conditions </strong></p></td><td style="height:17.9pt; vertical-align:top; width:195.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">edema</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">injection site reaction</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">chest pain</p></td><td style="height:17.9pt; vertical-align:top; width:81.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">* N = 7274</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&dagger; N = 3758 (women)</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"># pool of studies included IV and oral administration</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Table 5: Less Common (0.1 to 1%) Adverse Reactions Reported in Clinical Trials with levofloxacin (N = 7537)</strong></p><table style="width:0px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:5.85pt; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>System/Organ Class </strong></p></td><td style="height:5.85pt; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Adverse Reaction </strong></p></td></tr><tr><td style="height:5.95pt; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Infections and Infestations </strong></p></td><td style="height:5.95pt; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">genital moniliasis</p></td></tr><tr><td style="height:23.15pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Blood and Lymphatic System Disorders </strong></p></td><td style="height:23.15pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">anemia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">thrombocytopenia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">granulocytopenia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]</p></td></tr><tr><td style="height:5.95pt; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Immune System Disorders </strong></p></td><td style="height:5.95pt; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">allergic reaction [see Special warnings and precautions]</p></td></tr><tr><td style="height:23.15pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Metabolism and Nutrition Disorders </strong></p></td><td style="height:23.15pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hyperglycemia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hypoglycemia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]<em> </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hyperkalemia</p></td></tr><tr><td style="border-color:black; height:130.45pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Psychiatric Disorders </strong></p></td><td style="height:130.45pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">anxiety</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">agitation</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">confusion</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">depression</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hallucination</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">nightmare*</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]<em> </em></p><p style="margin-right:4.5pt; text-align:left">sleep disorder*</p><p style="margin-right:4.5pt; text-align:left">anorexia</p><p style="margin-right:4.5pt; text-align:left">abnormal dreaming*</p></td></tr><tr><td style="border-color:black; height:40.7pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Nervous System Disorders </strong></p></td><td style="height:40.7pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">tremor</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">convulsions</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">paresthesia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">vertigo</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hypertonia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hyperkinesias</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">abnormal gait</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">somnolence*</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">syncope</p></td></tr><tr><td style="border-color:black; height:28.7pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Respiratory, Thoracic and Mediastinal Disorders </strong></p></td><td style="height:28.7pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">epistaxis</p></td></tr><tr><td style="border-color:black; height:40.7pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Cardiac Disorders </strong></p></td><td style="height:40.7pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">cardiac arrest</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">palpitation</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ventricular tachycardia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ventricular arrhythmia</p></td></tr><tr><td style="border-color:black; height:17.5pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Vascular Disorders </strong></p></td><td style="height:17.5pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">phlebitis</p></td></tr><tr><td style="border-color:black; height:16.15pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Gastrointestinal Disorders </strong></p></td><td style="height:16.15pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">gastritis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">stomatitis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">pancreatitis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">esophagitis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">gastroenteritis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">glossitis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">pseudomembranous/ C. difficile colitis [see Special warnings and precautions]</p></td></tr><tr><td style="border-color:black; height:25.15pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Hepatobiliary Disorders </strong></p></td><td style="height:25.15pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">abnormal hepatic function</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">increased hepatic enzymes</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">increased alkaline phosphatase</p></td></tr><tr><td style="border-color:black; height:29.6pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Skin and Subcutaneous Tissue Disorders </strong></p></td><td style="height:29.6pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">urticaria [see Special warnings and precautions]</p></td></tr><tr><td style="border-color:black; height:29.6pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Musculoskeletal and Connective Tissue Disorders </strong></p></td><td style="height:29.6pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">arthralgia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">tendinitis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">myalgia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">skeletal pain</p></td></tr><tr><td style="border-color:black; height:25.15pt; vertical-align:top; width:158.0pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Renal and Urinary Disorders </strong></p></td><td style="height:25.15pt; vertical-align:top; width:288.45pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">abnormal renal function</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">acute renal failure [see Special warnings and precautions]</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">* N = 7274</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with quinolones, including levofloxacin. The relationship of the drugs to these events is not presently established.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Postmarketing Experience </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Table 6 lists adverse reactions that have been identified during post-approval use of levofloxacin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Table 6: Postmarketing Reports of Adverse Drug Reactions</strong></p><table style="width:0px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:6.6pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>System/Organ Class </strong></p></td><td style="border-color:black; height:6.6pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Adverse Reaction </strong></p></td></tr><tr><td style="border-color:black; height:34.9pt; vertical-align:top; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Blood and Lymphatic System Disorders </strong></p></td><td style="height:34.9pt; vertical-align:bottom; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">pancytopenia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">aplastic anemia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">leukopenia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hemolytic anemia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">eosinophilia</p></td></tr><tr><td style="border-color:black; height:34.9pt; vertical-align:top; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Immune System Disorders </strong></p></td><td style="height:34.9pt; vertical-align:bottom; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hypersensitivity reactions, sometimes fatal including: anaphylactic/anaphylactoid reactions</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">anaphylactic shock</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">angioneurotic edema</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">serum sickness</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]</p></td></tr><tr><td style="border-color:black; height:17.0pt; vertical-align:top; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Psychiatric Disorders </strong></p></td><td style="height:17.0pt; vertical-align:bottom; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">psychosis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">paranoia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">isolated reports of suicidal ideation, suicide attempt and completed suicide</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]</p></td></tr><tr><td style="border-color:black; height:63.8pt; vertical-align:top; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Nervous System Disorders </strong></p></td><td style="height:63.8pt; vertical-align:top; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">exacerbation of myasthenia [see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">anosmia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ageusia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">parosmia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">dysgeusia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">peripheral neuropathy (may be irreversible) [see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>&nbsp;</em>isolated reports of encephalopathy</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">abnormal electroencephalogram (EEG)</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">dysphonia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">pseudotumor cerebri [see Special warnings and precautions]</p></td></tr><tr><td style="border-color:black; height:29.2pt; vertical-align:top; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Eye Disorders </strong></p></td><td style="height:29.2pt; vertical-align:bottom; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">uveitis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">vision disturbance, including diplopia</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">visual acuity reduced</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">vision blurred</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">scotoma</p></td></tr><tr><td style="border-color:black; height:11.8pt; vertical-align:top; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Ear and Labyrinth Disorders </strong></p></td><td style="height:11.8pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hypoacusis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">tinnitus</p></td></tr><tr><td style="border-color:black; height:23.4pt; vertical-align:top; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Cardiac Disorders </strong></p></td><td style="height:23.4pt; vertical-align:top; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">isolated reports of torsade de pointes</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">electrocardiogram QT prolonged [see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">tachycardia</p></td></tr><tr><td style="border-color:black; height:6.1pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Vascular Disorders </strong></p></td><td style="height:6.1pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">vasodilatation</p></td></tr><tr><td style="border-color:black; height:11.85pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Respiratory, Thoracic and Mediastinal Disorders </strong></p></td><td style="height:11.85pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">isolated reports of allergic pneumonitis [see Special warnings and precautions]</p></td></tr><tr><td style="border-color:black; height:11.85pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Hepatobiliary Disorders </strong></p></td><td style="height:11.85pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hepatic failure (including fatal cases)</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">hepatitis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">jaundice</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions]</p></td></tr><tr><td style="border-color:black; height:11.85pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Skin and Subcutaneous Tissue Disorders </strong></p></td><td style="height:11.85pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">bullous eruptions to include:</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Stevens-Johnson Syndrome</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">toxic epidermal necrolysis</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Acute Generalized Exanthematous Pustulosis (AGEP) fixed drug eruptions</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">erythema multiforme</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">[see Special warnings and precautions] photosensitivity/phototoxicity reaction [see Special warnings and precautions]</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">leukocytoclastic vasculitis</p></td></tr><tr><td style="border-color:black; height:11.85pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Musculoskeletal and Connective Tissue Disorders </strong></p></td><td style="height:11.85pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">tendon rupture [see Special warnings and precautions] muscle injury, including rupture</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">rhabdomyolysis</p></td></tr><tr><td style="border-color:black; height:11.85pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Renal and Urinary Disorders </strong></p></td><td style="height:11.85pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">interstitial nephritis [see Special warnings and precautions]</p></td></tr><tr><td style="border-color:black; height:11.85pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>General Disorders and Administration Site Conditions </strong></p></td><td style="height:11.85pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">multi-organ failure</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">pyrexia</p></td></tr><tr><td style="border-color:black; height:11.85pt; width:155.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Investigations </strong></p></td><td style="height:11.85pt; width:276.85pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">prothrombin time prolonged</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">international normalized ratio prolonged</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">muscle enzymes increased</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&nbsp;</p><p style="text-align:left"><strong>To report any side effect(s): </strong></p><p style="text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Saudi Arabia: </strong></p><p style="text-align:left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Center (NPC)</p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">Fax: +966-11-205-7662</p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">Reporting hotline: 19999</p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">E-mail: npc.drug@sfda.gov.sa</p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">Website: www.sfda.gov.sa/npc</p><p style="text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>United Arab of Emirates:</strong></p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">P.O. Box:&nbsp;1853, Tel: 80011111</p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">Email:&nbsp;pv@moh.gov.ae</p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">Drug Department, Ministry of Health &amp; Prevention</p><p style="margin-left:35.1pt; margin-right:0cm; text-align:left">Dubai-UAE.</p><p style="margin-left:26.1pt; margin-right:0cm; text-align:left; text-indent:-13.5pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Other GCC States:</strong></p><p style="text-align:left">Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:4.5pt; text-align:justify">In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:justify; text-indent:.05pt">Levofloxacin<sup> </sup>exhibits a low potential for acute toxicity. Mice, rats, dogs and monkeys exhibited the following clinical signs after receiving a single high dose of levofloxacin: ataxia, ptosis, decreased locomotor activity, dyspnea, prostration, tremors, and convulsions. Doses in excess of 1500 mg/kg orally and 250 mg/kg IV produced significant mortality in rodents.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Mechanism of Action Levofloxacin is a member of the fluoroquinolone class of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The mean &plusmn; SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following administration of the oral tablets, are summarized in Table 8.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Table 8: Mean &plusmn; SD Levofloxacin PK Parameters</strong></p><p style="text-align:left"><!--[if !supportMisalignedColumns]--></p><p style="text-align:left"><!--[endif]--></p><table style="width:0px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:12.9pt; vertical-align:bottom; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Regimen</strong></p></td><td style="border-color:black; height:12.9pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Cmax (mcg/mL) </strong></p></td><td style="border-color:black; height:12.9pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Tmax (h) </strong></p></td><td style="border-color:black; height:12.9pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>AUC (mcg&middot;h/mL) </strong></p></td><td style="border-color:black; height:12.9pt; vertical-align:top; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>CL/F1 (mL/min) </strong></p></td><td style="border-color:black; height:12.9pt; vertical-align:top; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Vd/F2 (L) </strong></p></td><td style="border-color:black; height:12.9pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>t1/2 (h) </strong></p></td><td style="border-color:black; height:12.9pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>CLR (mL/min) </strong></p></td></tr><tr><td style="height:6.15pt; width:261.1pt" colspan="4"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Single dose </strong></p></td><td style="height:6.15pt" colspan="6"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">250 mg oral tablet<sup>3</sup></p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">2.8 &plusmn; 0.4</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.6 &plusmn; 1.0</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">27.2 &plusmn; 3.9</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">156 &plusmn; 20</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.3 &plusmn; 0.9</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">142 &plusmn; 21</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg oral tablet<sup>3</sup>*</p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5.1 &plusmn; 0.8</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.3 &plusmn; 0.6</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">47.9 &plusmn; 6.8</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">178 &plusmn; 28</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">6.3 &plusmn; 0.6</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">103 &plusmn; 30</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg oral tablet4*</p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">9.3 &plusmn; 1.6</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.6 &plusmn; 0.8</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">101 &plusmn; 20</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">129 &plusmn; 24</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">83 &plusmn; 17</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.5 &plusmn; 0.9</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td></tr><tr><td style="height:6.15pt; width:261.1pt" colspan="4"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Multiple dose </strong></p></td><td style="height:6.15pt" colspan="6"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">500 mg every 24h oral tablet<sup>3</sup></p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5.7 &plusmn; 1.4</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.1 &plusmn; 0.4</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">47.5 &plusmn; 6.7</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">175 &plusmn; 25</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">102 &plusmn; 22</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.6 &plusmn; 1.6</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">116 &plusmn; 31</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">750 mg every 24h oral tablet<sup>4</sup></p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">8.6 &plusmn; 1.9</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.4 &plusmn; 0.5</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">90.7 &plusmn; 17.6</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">143 &plusmn; 29</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">100 &plusmn; 16</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">8.8 &plusmn; 1.5</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">116 &plusmn; 28</p></td></tr><tr><td style="height:6.15pt; width:307.3pt" colspan="5"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>500 mg oral tablet single dose, effects of gender and age: </strong></p></td><td style="height:6.15pt" colspan="5"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="border-color:black; height:11.95pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Male<sup>5</sup></p></td><td style="height:11.95pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5.5 &plusmn; 1.1</p></td><td style="height:11.95pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.2 &plusmn; 0.4</p></td><td style="height:11.95pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">54.4 &plusmn; 18.9</p></td><td style="height:11.95pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">166 &plusmn; 44</p></td><td style="height:11.95pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">89 &plusmn; 13</p></td><td style="height:11.95pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.5 &plusmn; 2.1</p></td><td style="height:11.95pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">126 &plusmn; 38</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Female<sup>6</sup></p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.0 &plusmn; 1.6</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.7 &plusmn; 0.5</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">67.7 &plusmn; 24.2</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">136 &plusmn; 44</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">62 &plusmn; 16</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">6.1 &plusmn; 0.8</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">106 &plusmn; 40</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Young<sup>7</sup></p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5.5 &plusmn; 1.0</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.5 &plusmn; 0.6</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">47.5 &plusmn; 9.8</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">182 &plusmn; 35</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">83 &plusmn; 18</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">6.0 &plusmn; 0.9</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">140 &plusmn; 33</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Elderly<sup>8</sup></p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.0 &plusmn; 1.6</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.4 &plusmn; 0.5</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">74.7 &plusmn; 23.3</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">121 &plusmn; 33</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">67 &plusmn; 19</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.6 &plusmn; 2.0</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">91 &plusmn; 29</p></td></tr><tr><td style="height:6.2pt; width:324.15pt" colspan="7"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>500 mg oral single dose tablet, patients with renal impairment: </strong></p></td><td style="height:6.2pt" colspan="3"><p style="text-align:left">&nbsp;</p></td></tr><tr><td style="border-color:black; height:12.0pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">CLCR 50&ndash;80 mL/min</p></td><td style="height:12.0pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.5 &plusmn; 1.8</p></td><td style="height:12.0pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.5 &plusmn; 0.5</p></td><td style="height:12.0pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">95.6 &plusmn; 11.8</p></td><td style="height:12.0pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">88 &plusmn; 10</p></td><td style="height:12.0pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:12.0pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">9.1 &plusmn; 0.9</p></td><td style="height:12.0pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">57 &plusmn; 8</p></td></tr><tr><td style="border-color:black; height:6.15pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">CLCR 20&ndash;49 mL/min</p></td><td style="height:6.15pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">7.1 &plusmn; 3.1</p></td><td style="height:6.15pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">2.1 &plusmn; 1.3</p></td><td style="height:6.15pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">182.1 &plusmn; 62.6</p></td><td style="height:6.15pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">51 &plusmn; 19</p></td><td style="height:6.15pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:6.15pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">27 &plusmn; 10</p></td><td style="height:6.15pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">26 &plusmn; 13</p></td></tr><tr><td style="border-color:black; height:6.15pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">CLCR &lt;20 mL/min</p></td><td style="height:6.15pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">8.2 &plusmn; 2.6</p></td><td style="height:6.15pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.1 &plusmn; 1.0</p></td><td style="height:6.15pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">263.5 &plusmn; 72.5</p></td><td style="height:6.15pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">33 &plusmn; 8</p></td><td style="height:6.15pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:6.15pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">35 &plusmn; 5</p></td><td style="height:6.15pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">13 &plusmn; 3</p></td></tr><tr><td style="border-color:black; height:6.15pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Hemodialysis</p></td><td style="height:6.15pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">5.7 &plusmn; 1.0</p></td><td style="height:6.15pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">2.8 &plusmn; 2.2</p></td><td style="height:6.15pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:6.15pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:6.15pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:6.15pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">76 &plusmn; 42</p></td><td style="height:6.15pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td></tr><tr><td style="border-color:black; height:6.15pt; width:80.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">CAPD</p></td><td style="height:6.15pt; width:58.7pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">6.9 &plusmn; 2.3</p></td><td style="height:6.15pt; width:54.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1.4 &plusmn; 1.1</p></td><td style="height:6.15pt; width:67.25pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:6.15pt; width:54.55pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:6.15pt; width:41.95pt" colspan="2"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td><td style="height:6.15pt; width:41.55pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">51 &plusmn; 24</p></td><td style="height:6.15pt; width:42.65pt"><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND</p></td></tr><tr><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td><td style="text-align:left">&nbsp;</td></tr></tbody></table><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>1 </sup>clearance/bioavailability</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>2 </sup>volume of distribution/bioavailability</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>3 </sup>healthy males 18-53 years of age</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>4 </sup>healthy male and female subjects 18-54 years of age</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>5 </sup>healthy males 22-75 years of age</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>6 </sup>healthy females 18-80 years of age</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>7</sup>young healthy male and female subjects 18-36 years of age</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><sup>8 </sup>healthy elderly male and female subjects 66-80 years of age</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">* Absolute bioavailability; F=0.99 &plusmn; 0.08 from a 500 mg tablet and F=0.99 &plusmn; 0.06 from a 750 mg tablet;</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">ND=not determined.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Steady-state conditions are reached within 48 hours following a 500 mg or 750mg once-daily dosage regimen. The mean &plusmn; SD peak and trough plasma concentrations attained following multiple once-daily oral dosage regimens were approximately 5.7 &plusmn; 1.4 and 0.5 &plusmn; 0.2 mcg/mL after the 500 mg doses, and 8.6 &plusmn; 1.9 and 1.1 &plusmn; 0.4 mcg/mL after the 750 mg doses, respectively. The mean &plusmn; SD peak and trough plasma concentrations attained following multiple once-daily IV regimens were approximately 6.4 &plusmn; 0.8 and 0.6 &plusmn; 0.2 mcg/mL after the 500 mg doses, and 12.1 &plusmn; 4.1 and 1.3 &plusmn; 0.71 mcg/mL after the 750 mg doses, respectively.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Absorption </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Levofloxacin is rapidly and essentially completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The absolute bioavailability of levofloxacin from a 500 mg tablet and a 750 mg tablet of levofloxacin<sup> </sup>are both approximately 99%, demonstrating complete oral absorption of levofloxacin. Following a single intravenous dose of levofloxacin to healthy volunteers, the mean &plusmn; SD peak plasma concentration attained was 6.2 &plusmn; 1.0 mcg/mL after a 500 mg dose infused over 60 minutes and 11.5 &plusmn; 4.0 mcg/mL after a 750 mg dose infused over 90 minutes. Oral administration of a 500 mg dose of levofloxacin<sup> </sup>with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration. Therefore, levofloxacin<sup> </sup>Tablets can be administered without regard to food.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for levofloxacin<sup> </sup>Tablets when equal doses (mg/mg) are administered. Therefore, the oral and IV routes of administration can be considered interchangeable<em>. </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Distribution </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues. Levofloxacin reaches its peak levels in skin tissues and in blister fluid of healthy subjects at approximately 3 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2 and the blister fluid to plasma AUC ratio is approximately 1 following multiple once-daily oral administration of 750 mg and 500 mg doses of levofloxacin, respectively, to healthy subjects. Levofloxacin also penetrates well into lung tissues. Lung tissue concentrations were generally 2to 5-fold higher than plasma concentrations and ranged from approximately 2.4 to 11.3 mcg/g over a 24-hour period after a single 500 mg oral dose.</p><p style="margin-right:4.5pt; text-align:left"><em>In vitro</em>, over a clinically relevant range (1 to 10 mcg/mL) of serum/plasma levofloxacin concentrations, levofloxacin is approximately 24 to 38% bound to serum proteins across all species studied, as determined by the equilibrium dialysis method. Levofloxacin is mainly bound to serum albumin in humans. Levofloxacin binding to serum proteins is independent of the drug concentration.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Elimination </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong><em><u>Metabolism </u></em></strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong><em><u>Excretion </u></em></strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously. The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of levofloxacin occurs in addition to its glomerular filtration. Concomitant administration of either cimetidine or probenecid results in approximately 24% and 35% reduction in the levofloxacin renal clearance, respectively, indicating that secretion of levofloxacin occurs in the renal proximal tubule. No levofloxacin crystals were found in any of the urine samples freshly collected from subjects receiving levofloacin.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Microbiology </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Mechanism of Action </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Resistance </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Fluoroquinolone resistance can arise through mutations in defined regions of DNA gyrase or topoisomerase IV, termed the Quinolone-Resistance Determining Regions (QRDRs), or through altered efflux.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from aminoglycosides, macrolides and &beta;-lactam antibiotics, including penicillins. Fluoroquinolones may, therefore, be active against bacteria resistant to these antimicrobials.</p><p style="margin-right:4.5pt; text-align:left">Resistance to levofloxacin due to spontaneous mutation <em>in vitro </em>is a rare occurrence (range: 10<sup>-9 </sup>to 10<sup>-10</sup>). Cross-resistance has been observed between levofloxacin and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to levofloxacin.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Antimicrobial Activity </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Levofloxacin has <em>in vitro </em>activity against Gram-negative and Gram-positive bacteria.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Levofloxacin has been shown to be active against most isolates of the following bacteria both <em>in vitro </em>and in clinical infections as described in Therapeutic indications:</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Aerobic bacteria</strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Gram-Positive Bacteria </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Enterococcus faecalis </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Staphylococcus aureus </em>(methicillin-susceptible isolates)</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Staphylococcus epidermidis </em>(methicillin-susceptible isolates)</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Staphylococcus saprophyticus </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Streptococcus pneumoniae </em>(including multi-drug resistant isolates [MDRSP]<sup>1</sup>) Streptococcus pyogenes</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Gram-Negative Bacteria </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Enterobacter cloacae </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Escherichia coli </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Haemophilus influenzae </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Haemophilus parainfluenzae </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Klebsiella pneumoniae </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Legionella pneumophila </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Moraxella catarrhalis </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Proteus mirabilis </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Pseudomonas aeruginosa </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Serratia marcescens </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">1 MDRSP (Multi-drug resistant <em>Streptococcus pneumoniae</em>) isolates are isolates resistant to two or more of the following antibiotics: penicillin (MIC &ge;2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime; macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Other microorganisms </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Chlamydophila pneumoniae </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Mycoplasma pneumoniae </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">The following <em>in vitro </em>data are available, <u>but their clinical significance is unknown: </u>Levofloxacin exhibits <em>in vitro </em>minimum inhibitory concentrations (MIC values) of 2 mcg/mL or less against most (&ge;90%) isolates of the following microorganisms; however, the safety and effectiveness of levofloxacin<sup> </sup>in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Aerobic bacteria </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Gram-Positive Bacteria </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Staphylococcus haemolyticus </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>&beta;-hemolytic Streptococcus (Group C/F) </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">&beta;-hemolytic <em>Streptococcus (Group G) </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Streptococcus agalactiae </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Streptococcus milleri </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left">Viridans group <em>streptococci </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Bacillus anthracis </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Gram-Negative Bacteria </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Acinetobacter baumannii </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Acinetobacter lwoffii </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Bordetella pertussis </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Citrobacter koseri </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Citrobacter freundii</em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Enterobacter aerogenes</em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Enterobacter sakazakii </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Klebsiella oxytoca </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Morganella morganii </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Pantoea agglomerans </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Proteus vulgaris </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Providencia rettgeri </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Providencia stuartii </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Pseudomonas fluorescens </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Yersinia pestis </em></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Anaerobic bacteria </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><strong>Gram-Positive Bacteria </strong></p><p style="margin-left:0cm; margin-right:4.5pt; text-align:left"><em>Clostridium perfringens</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">The other ingredients are Microcrystalline cellulose, sodium starch glycolate, Povidone K30, colloidal anhydrus silica, magnesium stearate, Opadry OY-L white, black iron oxide, yellow iron oxide, polyethylene glycol 6000</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:4.5pt; text-align:justify"><strong>Nevotic<sup>&reg;</sup> 500mg F/C Tablet</strong>, Beige to brownish yellow oval deep biconvex film coated tablet engraved with PhI on one face, packed in PVDC/ Alu blisters, intended for oral use.</p><p style="margin-left:0cm; margin-right:4.5pt; text-align:justify"><strong>Pack size: </strong>7 film coated tablets/blister /Pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharma International Company
Amman - Jordan
Tel: 00962-6-5158890 / 5157893
Fax: 00962-6-5154753
Email: marketing@pic-jo.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>